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Figure 1. Intracellular compartments (Alberts, et al., 2004) 
The major intracellular compartments of an animal cell are the 
cytosol, endoplasmic reticulum (ER), Golgi apparatus, mitochondria, 
endosomes and lysosomes. The ER encloses about half of the total 
membrane area. The majority of the ER membrane is ribosome 
bound, forming the rough ER. The part of ER which is oriented to 
the Golgi apparatus typically lacks ribosomes: smooth ER. This part 
represents the exit site of secretory proteins (Alberts, et al., 2004). 
 
1. Introduction 
1.1. Endoplasmic Reticulum 
The endoplasmic reticulum (ER) is an organelle found in all eukaryotic cells. It has 
many functions including protein folding and modification, quality control of 
proteins, biogenesis of organelles and Ca2+ homeostasis (Kleizan & Braakman, 2004). 
ER is the central part of the secretory pathway and it has evolved into a staging 
ground for secretory protein synthesis. The secretory proteins are mostly 
synthesized by polyribosomes bound to the ER membrane. Through a translocation 
channel (Sec61), the proteins are co-translationally transported to the ER lumen, or 
inserted into the ER membrane (Benyair, et al., 2011).  
The ER is a unique compartment 
where a set of covalent protein 
modifications take place, 
including the removal of the 
signal sequence and glycosyl-
phosphatidylinositol (GPI) 
anchor addition (Anelli & Sitia, 
2008). Further, the ER lumen 
provides a safe environment for 
protein folding, due to the 
oxidative conditions which 
facilitate the disulfide bond 
formation, and it is loaded with 
molecular chaperones which 
facilitate protein folding and 
prevent the formation of aggregates (Brodsky & Skach, 2011). 
The ER is organized into a netlike labyrinth of branching tubules and flattened sacs 
(see figure 1). Its membrane constitutes more than half of the total membrane of an 
average animal cell. The tubules and sacs are connected, and their membranes are 
continuous with the outer nuclear membrane. The membrane is enclosing the so 
called ER lumen where protein folding and modification take place (Alberts, et al., 
2008). 
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ER subcompartment Main functions 
Rough ER Protein synthesis and folding 
Smooth ER Lipid synthesis, calcium storage 
Nuclear envelope Delineates nucleus 
MAM ER/mitochondria calcium homeostasis, apoptotic calcium signaling, lipid transfer 
ERQC Export of unfolded proteins to the proteasome 
ERES Export of proteins from ER to Golgi 
PAM Calcium import from extracellular space, sterol trafficking to plasma membrane 
Russell bodies Segregation of protein aggregates 
Lipid droplets Storage of triacylglycerides 
Table 1. ER subcompartments and their functions (Lynes & Simmen, 2011) 
 
Two main ER membrane regions can be distinguished: rough endoplasmic reticulum 
(rough ER) and smooth endoplasmic reticulum (smooth ER). The rough ER is the 
place of ribosomal attachment and protein biosynthesis, whereas the smooth ER 
lacks bound ribosomes. The smooth ER represents the exit site of proteins; ER exit 
sites (ERES). However, in specialized cells the smooth ER has additional functions 
(Alberts, et al., 2008). The smooth ER can form interfaces with other compartments 
like lysosomes; the Golgi-ER-lysosome compartment (GERL) and mitochondria; the 
ER-mitochondria interface (MAM). In addition, there are other smooth ER domains, 
including the plasma domain (PAM) and the ER quality control compartment (ERQC). 
On ERES, where the export of proteins is mediated, an intermediate compartment is 
generated; ER-Golgi intermediate compartment (ERGIC) (Lynes & Simmen, 2011). An 
overview of ER subcompartments is shown in table 1.  
1.2. Protein synthesis in the ER 
The synthesis of mammalian secretory and membrane proteins begins in the cytosol 
(Kleizan & Braakman, 2004). Then these proteins are bound by the signal recognition 
particle (SRP), which recognizes the proteins ER signal sequence and temporarily 
stops their elongation. These complexes are directed together with the ribosomes to 
the ER via the SRP receptor (SRP-R), where the synthesis continues (Alberts, et al., 
2004). The ribosomes and protein translocation channels (translocons) mediate the 
production of secretory proteins. These translocons are made up of more than 20 
polypeptides and are associated with the translocones associated protein complex 
(TRAP), translocating chain associated membrane protein (TRAM), 
oligosaccharyltransferase (OST), signal peptidase, SRP-R and accessory proteins 
(Lynes & Simmen, 2011). The growing polypeptide chains co-translationally enter the 
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Figure 2. Cotranslational synthesis of proteins on the ER membrane (Kampmann & Blobel, 2009) 
(A) Protein synthesis of ER resident and secretory proteins begins in the Cytosol. (B) The destination of proteins 
depends on the signal sequence which is synthesized in the polypeptide. Proteins without a signal sequence remains 
in the cytosol. (C) ER signal sequences are recognized by the Signal Recognition Particle (SRP) which binds to the 
polypeptide and the ribosomes, and temporally stops the synthesis. (D) The SRP-polypeptide-ribosome complex is 
recognized by the SRP receptor which is located on the ER membrane. This receptor recruits the complex to the 
translocon. After recruitment, the SRP and SRP receptor dissociate from the ribosome-polypeptide-translocon 
complex. (E, F, G) The growing polypeptide enters the ER lumen. (H) The ribosomes dissociate and bind to new 
transcripts (Kampmann & Blobel, 2009).   
 ER through the Sec61 complex in an unfolded state (see figure 2) (Hebert, et al., 
2009). Folding of these polypeptides starts immediately once the growing chain 
emerges in the ER lumen (Bagola, et al., 2011). The co-translational folding of 
proteins allows a sequential folding of the proteins, which greatly increases the 
folding efficiency (Kleizen & Braakman, 2004). 
While entering the ER lumen, the polypeptides encounter a network of chaperones, 
which minimize aggregation, facilitate the formation of native structures and ensure 
oligomeric assembly. This network of chaperone systems involves i) non-covalent 
interactions with Hsp40, Hsp70 (Grp78/BiP/Kar2) and Hsp90 (Grp94) chaperones, 
ii) lectin based chaperones like calnexin (CNX) and calreticulin (CRT), and iii) protein 
disulfide isomerases (PDI) (Brodsky & Skach, 2011).  
1.3. Glycosylation of proteins 
The majority of secretory proteins are N-linked glycoproteins. During translocation 
across the ER membrane into the ER lumen, a precursor oligosaccharide is 
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Figure 3. Protein glycosylation in the ER (Gilmore, 2011) 
Most of the secretory proteins are N-glycosylated. The glycosylation is mediated by OST, a protein complex which 
transfers a precursor oligosaccharide from dolichol pyrophosphate to a consensus sequence of the growing 
polypeptide chain. Most commonly the polypeptide is transferred to a N-X-S or N-X-T sequence (Alberts, et al., 2008).  
 
transferred to the NH2 group of an asparagine, which is part of the consensus 
sequence asparagine-X-serine/threonine, where X can be any amino acid except 
proline (Alberts, et al., 2008). This central reaction of the pathway is mediated by OST 
which is a protein complex located in the membrane of the ER (see figure 3). The 
preformed oligosaccharide is transferred from a lipid linked oligosaccharide (LLO) 
donor (Mohorko, et al., 2011).  
Glc3Man9GlcNAc2 is the preferred substrate of eukaryotic OST (see figure 4). 
However, it was shown that different oligosaccharides can also serve as a substrate 
for the OST. The minimal glycan substrate of OST that still leads to a N-glycosidic 
linkage is the dolichol-linked monosaccharide Dol-PP-GlcNAc (Mohorko, et al., 2011).  
For long time it was unclear why such a large oligosaccharide precursor 
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Figure 4. The N-linked glycan (Alberts, et al., 2004)  
The precursor oligosaccharide is composed of three 
glucose molecules (green), nine mannose molecules 
(blue) and two N-acetylglucosamins (red): 
Glc3Man9GlcNAc2. In the ER the glycans are 
extensively trimmed and therefore in many 
glycoproteins only the core region of the glycans 
survives (highlighted with the gray box) (Alberts, et 
al., 2008).   
(Glc3Man9GlcNAc2) is used for protein N-
glycosylation, if it will later be extensively 
trimmed (Lederkremer, 2009). Nowadays 
it is known that the addition of such a 
complex N-glycan provides a molecular tag 
that can promote the folding, maturation, 
and quality control of a precursor. A defect 
N-glycosylation machinery can cause 
pathological consequences. (Wilson & 
Roebuck, 2008).  
1.3.1. Oligosaccharyltransferase (OST) 
The human OST is a heptameric complex 
containing the subunits ribophorin I, 
ribophorin II, OST48, OST4, Stt3p, 
N33/Tusc3 and IAP, and DAD1 (see figure 
5) (Mohorko, et al., 2011). The catalytic 
center of the OST complex lies within the 
Stt3 subunit. In mammals, two STT3 
isoforms exist: Stt3A and Stt3B (Wilson & 
Roebuck, 2008). Stt3 is the largest and 
most conserved polypeptide of the OST 
complex (Mohorko, et al., 2011). In the 
multimeric OST, some of the additional 
subunits fine-tune the glycosylation 
process (Schwarz & Aebi, 2011).  
1.3.2. Ribophorin I 
Ribophorin I and II were the first identified subunits of the mammalian OST complex. 
It was initially proposed that ribophorin I recruits the dolichol bound glycan to the 
OST, and later studies suggested that ribophorin I might form part or all of the OST 
active site, although this now seems unlikely (High & Wilson, 2007). Ribophorin I is 
highly conserved among various species. The human ribophorin I sequence shows 
more than 90% similarity with homologous proteins in vertebrates (Mohorko, et al., 
2011).  
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Figure 5. Human oligosaccharyltransferase complex (OST).  
The human OST is a heptameric complex with following subunits: ribophorin I, ribophorin II, OST48, OST4, Stt3p, 
N33/Tusc3 and IAP, and DAD1. Some of the subunits have more isoforms, and therefore there are four variants of the 
human OST (Mohorko, et al., 2011).   
Ribophorin I is a 68-kDa transmembrane protein with a single transmembrane helix, 
a large luminal domain and a smaller C-terminal cytosolic domain 
(Chotwiwatthanakun, et al., 2008). The parts of both ribophorins oriented towards 
the cytosol most probably provide binding sites for translating ribosomes. 
Interactions between ribophorins and ribosomes were detected in cross linking 
experiments, and it was shown that antibodies against the C-terminal cytosolic 
domain of ribophorin I prevent ribosome targeting to the ER membrane and in this 
way inhibit protein translocation (Mohorko, et al., 2011). Ribophorin I probably 
improves the efficiency of N-glycosylation of selected substrates (Wilson & High, 
2007), but it is not essential for glycosylation per se (Mohorko, et al., 2011).  
1.4. The secretory pathway 
The secretory pathway ensures that newly synthesized proteins are delivered 
through the ER to their final destinations in the cell. It is also necessary for proteins to 
fold and to be modified (Reynaud & Simpson, 2002). The transported cargo includes 
membrane proteins, soluble proteins and secreted proteins. These proteins have a 
signal sequence in common which directs them to the ER where they are entering the 
secretory pathway (see above) (Bethune, et al., 2006). 
The central organelle of the secretory pathway is the ER where proteins are 
synthesized and prepared for their further journey. However, the secretory pathway 
also includes other organelles which are all collectively described as the 
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Figure 6. The different pathways of the coated vesicles (Alberts, et al., 2004) 
Clathrin coated vesicles are present in the late secretory pathway. They transport their cargo from the plasma membrane 
to the early endosomes, and between endosomes and the Golgi apparatus. COPI and COPII coated vesicles are part of 
the early secretory pathway. COPI coated vesicles transport their cargo within the Golgi, and from the Golgi to the ER. 
The anterograde transport (from ER to the Golgi) is mediated by the COPII coated vesicles.   (Lodish, et al., 2004).  
endomembrane system. These compartments are interconnected by vesicular traffic 
(see figure 6) (Glick, 2002). During the vesicular transport, the transport vesicles 
supply the compartments with the appropriate proteins and lipids. This process is 
tightly regulated by the cell, and it is vectorial; vesicles generated from a donor 
compartment will only fuse with the cognate acceptor membrane (Spang, 2008).  
So far three types of transport vesicles have been characterized in detail: i) coat 
protein complex I (COPI) - coated vesicles, ii) coat protein complex II (COPII) – coated 
vesicles and clathrin-coated vesicles (Gerdes, 2008). These vesicles are generated and 
fused by a number of processes in which different players are involved: GTPases, 
SNARE proteins and the cargo itself (see table 2) (Spang, 2008). A general scheme of 
coated vesicle formation is shown in figure 7. The clathrin coated vesicles transport 
their cargo from the plasma membrane and between endosomal and Golgi 
compartments. The COPI and COPII coated vesicles transport their cargo in the early 
secretory pathway: COPII coated vesicles transport their cargo from the ER exit sites 
to the Golgi (anterograde transport); COPI coated vesicles transport their cargo 
mainly within the Golgi apparatus and from the cis-Golgi to the ER (retrograde 
transport) (Lodish, et al., 2004).  The transport vesicles and the appropriate 
pathways are briefly described below. 
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Vesicle type Coat proteins Associated GTPase Main functions 
COPII 
Sec23/Sec24 and Sec13/Sec31 complexes, 
Sec16 
Sar1 ER to cis-Golgi 
COPI 
Coatomers containing seven different 
COP subunits 
ARF Cis-Golgi to ER, later to earlier Golgi cistern 
Clathrin and 
adapter 
proteins 
Clathrin + AP1 complexes ARF Trans-Golgi to endosome 
Clathrin + AP2 complexes ARF Plasma membrane to endosome 
Clathrin + GGA ARF Trans-Golgi to endosome 
Clathrin (?) + AP3 complexes ARF 
Golgi to lysosome, melanosome, or 
platelet vesicles 
Table 2. Coated vesicles involved in protein trafficking (Lodish, et al., 2004) 
 
1.4.1. COPII – coated vesicles: export from the ER 
Properly folded proteins are packed and transported further in the secretory 
pathway via COPII transport vesicles which, in most cell types, bud from the ER exit 
sites (ERES) (Glick, 2002). The ERES, which are relatively immobile structures, face 
out towards assemblies of vesicular-tubular structures called ER-Golgi intermediate 
compartment (ERGIC) clusters. These structures are cargo-rich compartments which 
mediate the trafficking of secretory proteins between ER and Golgi (Hughes & 
Stephens, 2008).  The ERGIC compartment is defined by the presence of ERGIC-53, 
which is a mannose - dependent lectin (Bethune, et al., 2006).  
To ERES, the GTPase Sar1 has to be recruited. This is done with the help of the 
guanine nucleotide exchange factor (GEF) Sec12. Further, a complex on the ER 
membrane is assembled by Sar1, the GTPase activating protein (GAP) Sec23, the 
cargo recruiter Sec24 and the cargo (Spang, 2008). Sec23 stimulates the hydrolysis of 
Sar1p-GTP to Sar1p-GDP which leads to the budding from the donor membrane 
(Murshid & Presley, 2004). 
1.4.2. COPI – coated vesicles: retrograde transport 
After the cargo leaves the ER membrane, it is found in the ERGIC. This compartment 
contains COPII and COPI markers: it is a interface between COPII and COPI mediated 
transport. From ERGIC, the cargo is transported to the cis-Golgi. This transport is 
probably COPI independent (Bethune, et al., 2006). The cargo moves from the cis site 
successively to the medial and trans cistern. During this journey, the proteins are 
additionally modified (Glick, 2002). The anterograde transport within the Golgi-
apparatus seems to be COPI dependent, as well as the retrograde transport of 
material back to the ER. In the trans-Golgi network the cargo is sorted for targeting to 
the final destinations: lysosomes, endosomes and the plasma membrane (Bethune, et 
al., 2006).  
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Figure 7. General scheme of coated vesicle formation (Pucadyil & Schmid, 2009) 
This process involves the initial assembly of coat subunits on the membrane, during which cargo recognition and 
sorting takes place, followed by maturation, during which the coat and underlying membrane acquire curvature. 
Scission of the coated bud finally generates a coated vesicle (Pucadyil & Schmid, 2009). 
Like COPII, the COPI coat is organized by a small GTPase. However, in this case the 
GTPase is ADP-ribosylation factor 1 (Arf1) instead of Sar1. The vesicle formation is 
not restricted to one compartment region, but can be formed at multiple distinct 
membranes along the early secretory pathway. The recruitment of Arf1 is mediated 
by a number of GEFs which all have a specific domain in common: Sec7 (Spang, 
2008). GBF1 is the major GEF involved in COPI vesicle biogenesis (Beck, et al., 2009). 
Through the GEF activity, the Arf1 conformation is changed and  in consequence an 
amphipathic helix is exposed, which allows a stable association of Arf1 with the 
membrane (Bethune, et al., 2006). Once Arf1 is membrane-bound, it can interact with 
SNARE proteins, GAPs and the cargo proteins. The GTP hydrolysis is not efficient at 
this time, but the GAP activity mediates the interaction with SNARE proteins. The 
main cargo recruiter is coatomer (derived from coat protomer) which acts to deform 
the membrane. Coatomer is a 550 kDa protein complex of seven subunits (Yu, et al., 
2012), from which at least three bind to different cargo motifs (Spang, 2008). 
Additionally, the coatomer also recruits transmembrane proteins from the p24 
family. They bind directly to the coatomer and increase the efficiency of vesicle 
formation (Beck, et al., 2009). Another critical component of the COPI vesicles is 
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brefeldin-A ADP-ribosylated substrate (BARS), which is critical for the fission step 
(Hsu & Yang, 2009).  
After the formation of COPI-coated vesicles, but before the fusion with the target 
membrane, the vesicles have to be uncoated.  This process is catalyzed by Arf1 
GTPase-activating proteins (Beck, et al., 2009). After uncoating, the vesicles are ready 
for fusion with the target membrane. Therefore, the vesicles are guided to the proper 
target with SNARE proteins and other factors (Kartberg, et al., 2005). 
1.4.3. Clathrin-coated vesicles: late secretory pathway 
Clathrin-coated vesicles are formed during endocytosis and in the late secretory 
pathway (vesicles which leave the trans-Golgi) (Buxbaum & Engelbert, 2007). The 
major protein of the clathrin-coated vesicles is clathrin itself. The subunits of clathrin 
form a three legged structure called triskelion. These structures assemble into a 
convex framework to form coated pits on the cytosolic surface of membranes 
(Alberts, et al., 2008).  
Like COPI, the GTP binding protein is the monomeric Arf1, which cycles between the 
inactive (GDP-bound) and active (GTP-bound) form (Lodish, et al., 2004). A number 
of adaptor proteins (AP1, AP2, AP3, AP4 and GGAs) function with Arf1 to generate the 
vesicle at the trans-Golgi and the endosomes (Spang, 2008).  
1.5. Quality Control in the ER 
The ER quality control of proteins is a topic of relatively recent interest. However, 
quality control in biological processes has long been a subject of intensive study 
(Määttänen, et al., 2010). For proteins, proof reading occurs at the level of 
transcription, translation, folding and assembly (Ellgaard & Helenius, 2003). After 
synthesis, proteins must rapidly fold to perform their biological activity. Folding takes 
place in three main sub-cellular compartments: cytosol, ER and mitochondria. Each 
organelle is equipped with a specific set of chaperones and folding enzymes 
optimized to work in the local conditions (Anelli & Sitia, 2008). An overview of the ER 
quality control is shown in figure 8. 
The presence of quality control in the ER is essential for several reasons. By 
preventing the premature exit of folding intermediates and incompletely assembled 
proteins from the ER, quality control extends the exposure of the substrates to the 
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Figure 8. Quality control in the early secretory pathway (Anelli & Sitia, 2008) 
A quality control machinery in the ER decides the fate of newly synthesized secretory proteins. If they are properly 
folded, that is if they obtain their native structure, the proteins will continue their journey through the secretory 
pathway. However, misfolded proteins are recognized in the ER and are retrotranslocated to the cytosol (ERAD). 
Accumulation of misfolded proteins can also induce the unfolded protein response (UPR) (Anelli & Sitia, 2008). 
 
folding machinery in the ER lumen and thereby improves the chance of correct 
maturation. This ensures that proteins are not dispatched to terminal compartments 
when they are still incompletely folded and therefore potentially damaging to the cell 
(Ellgaard & Helenius, 2003).  The quality control of secretory proteins requires the 
retention of nascent, unfolded proteins which are synthesized into the lumen of the 
ER and must be retained until proper folding is achieved (Benyair, et al., 2011).  
The majority of the proteins traversing the secretory pathway in eukaryotic cells are 
N-glycosylated glycoproteins. An elaborate quality control mechanism ensures that 
only correctly folded and processed glycoproteins exit the ER. In recent years it has 
become clear that the timing of this interval is linked to trimming of the sugar tree. 
(Avezov, et al., 2008).  
Association of nascent glycoproteins with the lectin chaperone calnexin (CNX), or its 
soluble homolog calreticulin (CRT), and examination by the folding sensor UDP 
glucose glycoprotein glucosyltransferase (UGGT) play a central role in ER retention, 
proper folding, and sensing of terminally misfolded glycoproteins. It appears that all 
misfolded glycoproteins are sent to ERAD through what is known as the CNX cycle 
(Benyair, et al., 2011). 
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Class Name Localization Function 
Chaperones 
BiP/GRP78 ER 
Folding assistant/unfolding; regulation of IRE1, PERK and ATF6 in ER 
signaling; Translocon gating and regulation 
GRP94 ER Folding assistant 
ORP150 ER Folding assistant, hypoxia 
HERP ER membrane ERAD 
SEL1L ER membrane ERAD 
Co-chaperones 
Sil1/BAP ER ATP exchange factor 
ERdjs ER BiP cofactors 
Lectins 
CNX ER membrane Folding 
CRT ER soluble Folding 
ERGIC-53 ERGIC Transport F5, F8, CatZ, CatC, IgM polymers 
VIPL ER Transport 
VIP-36 Cis-Golgi Transport 
EDEM1, 2, 3 ER subregion ERAD 
OS9 ER membrane ERAD 
Erlectin/XTP3-
B 
ER membrane ERAD 
Enzymes redox 
Ero1 ER + ERGIC Oxidase 
Ero1 ER Oxidase 
PDI ER Oxidase, isomerase, reductase 
ERp57 ER Isomerase, oxidase (?) 
ERp72 ER Unclear 
ERp44 ERGIC-cis-Golgi Thiol-mediated retention/IP3 R1 regulation 
Sugar 
processing 
Glucosidase I ER Sugar processing 
Glucosidase II ER Sugar processing 
ER Man I ER Sugar processing 
ER Man II ER Sugar processing 
UGGT ER Folding sensor and sugar processing 
Man IA, IB, IC Golgi Sugar processing 
Table 3. Incomplete list of ER factors (Anelli & Sitia, 2008) 
 
1.5.1. ER chaperones 
Molecular chaperones are present in different cellular compartments, but they are 
particularly important in the ER because of the high protein density in its lumen. The 
abundance of molecular chaperones in the ER ensures that exposed hydrophobic 
patches of misfolded proteins, nascent proteins and proteins in intermediate forms of 
folding are concealed. However, the ER lumen is not only populated by a variety of 
folding chaperones (Hsp70, Hsp90 and Hsp40 members), but also with lectin 
chaperones and various proteins essential for disulfide bond formation (Benyair, et 
al., 2011).  An incomplete list of the ER machinery is shown in table 3. 
A central question in the ER quality control processes is: How are the incorrect 
components recognized and discriminated from the correct ones? In the secretory 
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Figure 9. Glycoprotein trimming and the consequences (Lederkremer, 2009). 
The precursor oligosaccharide (G3M9), attached to Asn on the nascent polypeptide chain is trimmed by removal of the 
non-reducing terminal glucose residue by glucosidase I (GI) toG2M9 and of the second glucose by glucosidase II (GII) to 
G1M9, allowing binding of calnexin (CNX) or calreticulin (CRT). CNX folding cycles then start, where the glycoprotein is 
deglucosylated by GII and reglucosylated by UDPGlc:glycoprotein glucosyltransferase (GT). If the glycoprotein is 
properly folded, it is no longer recognized as a substrate by GT and it exits to the Golgi where it is further trimmed of all 
its α1,2 linked mannose residues (blue) by Golgi mannosidases IA, IB and IC to Man5GlcNAc2 (M5). If the glycoprotein 
cannot fold successfully, it is delivered to the ER-derived quality control compartment (ERQC) and further trimmed to 
M6 and M5 by ERManI with the assistance of the EDEMs 1-3, and possibly of recycled Golgi α1,2 mannosidases 
(Lederkremer, 2009).   
 
pathway the folding status of glycoproteins passing through the ER is marked by the 
composition of the N-glycan. The different glycoforms are recognized by specialized 
lectins (Määttänen, et al., 2010).  A number of ER lectins are specific to a wide range 
of glycan specificities. The most important ER lectins are CNX and the closely related 
luminal variant CRT. Both have specificity for Glc1Man9GlcNAc2 N-glycan that can be 
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generated by the action of glucosidase II on the Glc2Man9GlcNAc2 after processing of 
Glc3Man9GlcNAc2 by glucosidase I (Määttänen, et al., 2010). The trimming of N-
glycans is illustrated in figure 9.    
1.5.1.1. Calreticulin (CRT) 
CNX and CRT are conserved from plants through fungi to mammals, although their 
cycles of operation may differ between species (Benyair, et al., 2011). CRT is a soluble 
46-kDa protein of the ER lumen. It consists of three distinct structural domains with 
different functions: the N-terminal domain which is highly conserved between 
species and plays an important role in chaperone activity, the P-domain which is 
proline rich and also takes part in the chaperone activity, and finally the C-terminal 
domain which is responsible for Ca2+ buffering activity (Wang, et al., 2012).   
The main function of CRT is in the CRT/CNX cycle (in the ER lumen) where it 
interacts with CNX and an ER oxidoreductase of 57-kDa (ERp57).  However, 
immunogold labeling studies indicate that CRT is also found outside the ER, and there 
are implications that CRT plays a role in a variety of processes that occur outside the 
ER lumen, including the cell surface, cytoplasm and within the nucleus (Michalak, et 
al., 2009).  
1.5.1.2. Calnexin (CNX) 
CNX is a 90 kDa type I ER membrane protein, with the most part located within the 
ER lumen (Williams, 2006). CNX shares 42-78% sequence identity with CRT, with the 
highest homology in the proline rich calcium binding P-domain. It is composed of a 
luminal domain (highly homologous to CRT), a transmembrane domain and a short 
cytosolic domain of 88 amino acids. Like CRT, it mainly acts as a chaperone 
preventing the export of incorrectly or incompletely folded glycoproteins. It also 
helps to prevent rapid degradation (Bedard, et al., 2005). 
The carbohydrate binding domain of CNX is located in the globular domain, consisting 
of a number of ß sheets. The globular domain also contains a Ca2+ binding site 
(Benyair, et al., 2011). Like CRT, CNX is predominantly located in the ER but can also 
be found at the cell surface of a number of cells (Bedard, et al., 2005).  
1.5.2. CNX cycle 
Immediately after protein glycosylation (Glc3Man9GlcNAc2) in the ER, the glycan 
processing begins. In the first step, the glucosidase I (GI) cleaves the outermost 
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glucose, which occurs very rapidly, since it can be detected concomitantly with glycan 
transfer. This glycan composition prevents reassociation with the OST (Pearse & 
Hebert, 2010). The first hydrolysis is followed by sequential removal of the remaining 
two glucose residues by glucosidase II (GII) (D'Alessio, et al., 2010).  
GII is a heterodimeric protein consisting of  and  subunits. The  subunit contains a 
mannose 6-phosphate receptor homology (MRH) domain, which is suggesting a 
pathway in which the  subunit initially binds to the mannose residue of one 
oligosaccharide while the  subunit cleaves the glucose residues of another 
oligosaccharide. Following this cleavage (if at least two N – linked glycans are present 
in the glycoprotein), the  subunit may bind to the monoglucosylated oligosaccharide 
and allow the  subunit to process the glycoprotein until a non-glucosylated 
substrate is produced (Benyair, et al., 2011). Since there is only a single active site 
within GII, it is a slow digestion, which is the result of reorientation of the active site 
of the  subunit (Pearse & Hebert, 2010). 
Until recently, it was not known if there are ER proteins that interact with the 
intermediate Glc2Man9GlcNAc2 glycoprotein. However, recent studies have 
identified malectin, an ER membrane bound Glc2 specific lectin (Pearse & Hebert, 
2010).  Malectin seems to inhibit secretion of misfolded proteins and to modulate the 
second step trimming by GII (Benyair, et al., 2011).  It is a potential new component 
in the ER QC, but it is not fully understood which role it plays (Määttänen, et al., 
2010).  
Once GI and GII remove the two outermost glucose residues, the Glc1Man9GlcNAc2 
glycoprotein can be recognized by CNX and/or CRT (Williams, 2006). The 
transmembrane CNX interacts with both, membrane bound and soluble substrates, 
whereas the soluble CRT is more frequently associated with soluble substrates 
(Benyair, et al., 2011). These chaperones bind to the glycoprotein substrates in a 
Ca2+ dependent fashion (Pearse & Hebert, 2010). The binding of CNX and/or CRT to 
unfolded, monoglucosylated proteins grants such proteins time to achieve their 
native conformation by slowing folding events and allowing them to occur in a 
controlled manner. After binding to the substrate, they also recruit the 
oxidoreductase ERp57, which is an ER resident protein disulfide isomerase family 
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member. The trimeric complex CNX/CRT-ERp57-substrate promotes formation of 
disulfide bonds in the substrate protein (Jessop, et al., 2009).  ERp57 binds to one of 
the lectin chaperones through an interaction of a positively charged patch on a 
thioredoxin domain, and the negatively charged tip of the chaperone P domain 
(Pearse & Hebert, 2010). The importance of the CNX/CRT-ERp57 interaction was 
shown in experiments with a point mutation, which abrogates this interaction and 
greatly diminishes the ability of ERp57 to form mixed disulfides with proteins in the 
ER (Määttänen, et al., 2010). The formation of disulfide bonds and their isomerization 
enhance the proper glycoprotein folding (Williams, 2006).  
The glycoproteins remain in the CNX cycle as long as they are monoglucosylated: they 
are released by the second GII cleavage of the terminal glucose molecule. This most 
likely occurs irrespective of the folding state of the protein and prevents its renewed 
association with one of the two lectin chaperones (Ellgaard & Frickel, 2003). By 
abolishing the substrate-chaperone interaction, properly folded glycoproteins can 
pursue their transit through thesecretory pathway (Stigliano, et al., 2011). Released 
misfolded proteins are retained in the ER by entering the CNX cycle again (Williams, 
2006).  
The central protein in this pathway is UGGT. UGGT is a unique 175 kDa soluble ER 
protein (Kleizen & Braakman, 2004) which specifically glucosylates non-native, non-
glucosylated proteins (Stigliano, et al., 2011). Still, the structure is not fully analyzed, 
but UGGT is most probably a homodimer with the catalytic region at the C-terminus 
and the sensor domain at the N-terminus (Määttänen, et al., 2010). The misfolded 
proteins become re-glucosylated by UGGT, which leads to a new round of CNX/CRT 
binding (Dalbey & Von Heijne, 2002). UGGT recognizes the N-linked core of the 
Man3GlcNAc2 glycoprotein and senses the exposed hydrophobic regions found in 
unfolded or misfolded proteins (Benyair, et al., 2011). It has been shown that UGGT 
cannot only detect misfoldings on a domain level, but also local folding defects 
(Ellgaard & Frickel, 2003).  
UGGT and GII are opposite players and their activities hold glycoproteins in the CNX 
cycle. Theoretically, misfolded or/and unfolded glycoproteins could re-enter the CNX 
cycle over and over again, and in this way be retained in the ER lumen. This, however, 
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Figure 10. The CNX cycle (Anelli & Sitia, 2008)  
The CNX/CRT cycle. After transfer of the preformed core oligosaccharide (Glc3Man9GlcNAc2) onto nascent proteins, 
glucosidase I and II sequentially remove the two terminal glucoses from the A branch. The monoglucosylated 
Glc1Man9GlcNAc2 unfolded protein can now interact with the lectin chaperones CNX and CRT. In association with 
the oxidoreductase ERp57, CNX and CRT prevent aggregation and facilitate glycoprotein folding. Removal of the last 
glucose by glucosidase II (Man9GlcNAc2) interrupts the interaction of the protein with CNX/CRT. If the protein has 
attained its native structure, it can now proceed along the secretory pathway by bulk flow or by interaction with 
specific lectin transporters such as ERGIC-53 or VIPL. If unfolding persists, the glycoprotein is recognized by UGGT, 
which places a single glucose back onto the A branch, causing the protein to enter the CNX/CRT cycle again. Mannose 
trimming causes exit from the CNX/CRT cycle. Misfolded proteins can be recognized by specific lectins (EDEMs, OS9, 
etc) and targeted to degradation (Anelli & Sitia, 2008). 
would bring about an accumulation of glycoproteins in the ER and cause pathological 
consequences. Therefore, a timing mechanism is necessary to remove terminally 
misfolded glycoproteins from the ER avoid accumulation (Benyair, et al., 2011). The 
crucial step of removing the glycoproteins from the CNX cycle is another trimming of 
the glycan: the cleavage of the 1,2 linked mannose residues. This crucial step is done 
by ER mannosidases and is the initial step of the ER associated degradation (ERAD) of 
the misfolded proteins (Lederkremer, 2009). In mammalian cells, the glycoproteins 
can be trimmed from Man9GlcNAc2 to Man5GlcNAc2 or Man6GlcNAc2 (M6 or M5 
species). Due to the lack of the mannose residue, which is the acceptor for the glucose 
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Figure 11. Overview of the ERAD pathway (Vembar & Brodsky, 2008) 
After terminally misfolded proteins have been recognized (a), they are targeted to the retrotranslocon (b). After the 
retrotranslocation initiation (c), the substrates are polyubiquitinated by ubiquitin ligases (d). Once retrotranslocated, 
the substrates are targeted to the proteasome (e) (Vembar & Brodsky, 2008) 
transfer by GII, the glycoproteins can escape from the CNX cycle (Frenkel, et al., 
2003). An overview of the CNX cycle and its key players is shown in figure 10.  
1.5.3. ER-associated degradation (ERAD) 
Proteins that are unable to pass the ER quality control are identified and destroyed by 
the ER-associated degradation (ERAD) machinery. Therefore the terminally 
misfolded proteins are identified and retrotranslocated to the cytosol where they are 
degraded by the proteasome (Brodsky & Skach, 2011). The general principle of ERAD 
is illustrated in figure 11. 
The ERAD substrates can be categorized in three groups, depending on the 
localization of the lesion: i) ERAD-L substrates contain lesions in their luminal 
domain, ii) ERAD-C substrates contain lesions in the cytosolic domain and iii) ERAD-
M substrates contain lesions in the transmembrane domain. Depending on the 
substrate, the ERAD pathway can vary in the factor composition, but the principles 
appear to be similar (Benyair, et al., 2011). A list of established ERAD factors is shown 
in table 4.  
1.5.3.1. Recognition of irreparably misfolded proteins 
In the case of N-glucosylated proteins, the glycans do not only play an important role 
in glycoprotein entering or leaving the CNX cycle in which the proteins have time to 
fold, but they also can serve as degradation signals (Ushioda & Nagata, 2011). 
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Yeast Mammals Localization Function 
Hrd1 Hrd1/synoviolin Integral ER membrane Ubiquitin ligase 
/ Gp78/AMFR Integral ER membrane Ubiquitin ligase 
Doa10 Teb4/MARCH6 Integral ER membrane Ubiquitin ligase 
/ TRC8 Integral ER membrane Ubiquitin ligase 
/ RNF/RMA1 Integral ER membrane Ubiquitin ligase 
/ RFP2 Integral ER membrane, cytosolic Ubiquitin ligase 
/ CHIP cytosolic Ubiquitin ligase 
/ Parkin cytosolic Ubiquitin ligase 
Hrd3 SEL1L Integral ER membrane Substrate recruitment factor for Hrd1 
Yos9 OS9, XTP3-B ER lumen, associated with Hrd3/Sel1L Substrate recruitment factor for Hrd1 
Ubc6 Ubc6, Ubc6ep Integral ER membrane Ubiquitin conjugating enzyme 
Ubc7 Ube2g2 Cytosolic; associated with ER membrane Ubiquitin conjugating enzyme 
Cue1 / Integral ER membrane Recruits and activates Ubc7 
Usa1 HERP Integral ER membrane Scaffolding protein for the Hrd1 ligase 
Der1 Derlin 1,2,3 Integral ER membrane Components of a dislocation channel (?) 
Ubx2 Erasin/UBXD2 Integral ER membrane Recruits Cdc48/p97 to the ERAD ligases 
Cdc48/Npl4/Ufd1 p97/Npl4/Ufd1 Cytosolic Ubiquitin specific AAA-ATPase 
Table 4. ERAD factors in yeast and mammals (Benyair, et al., 2011). 
 
Properly folded proteins do not re-enter the CNX cycle, but continue their journey 
through the secretory pathway. However, one of central questions is how cells 
recognize that N-glycosylated proteins are irreparably misfolded, and prevent their 
re-entering in the CNX cycle. Intensive work has been dedicated to this issue, but 
there is still no clear answer to the question as yet (Caramelo & Parodi, 2008). Due to 
the slow catalytic activity of ER mannosidases, a mannose timer hypothesis was 
postulated: the action of ER mannosidases is delayed, and therefore only 
glycoproteins with prolonged CNX/CRT association are targeted to ERAD (Määttänen, 
et al., 2010).    
1.5.3.2. Labeling of terminally misfolded proteins for ERAD 
Once the misfolded and/or unfolded proteins are recognized, trimming of the glycan 
and the removal of (1,2)-bonded mannose residues generate a recognition code for 
the ERAD machinery. It is known that ER mannosidase I (ERManI) plays a central role 
in the sequential trimming of the glycan, but nowadays it is known that the trimming 
is done by other mannosidases and mannosidase-like proteins as well: the EDEMs 1-
3, Golgi (1,2)-mannosidases, and members of the glycosyl hydrolase 47 family  
(Bagola, et al., 2011) (Benyair, et al., 2011).  
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Figure 12. The core Hrd1p/HRDP1 complex in yeast/mammals (Smith, et al., 2011)  
E3 ubiquitin ligases are the central organizers of all ERAD pathways. The prototype of the E3 ligase in yeast is the Hrd1 
complex, and in mammals the HRD1 complex (Stolz & Wolf, 2010).  
At low concentrations, ERManI removes only mannose-b (see figure 9). However, it 
has been shown that ERManI can be concentrated in the ER-derived quality control 
compartment (ERQC), which is located around the centrosomes in mammalian cells, 
and therefore becomes capable of removing all four (1,2)-mannoses (Lederkremer, 
2009). The concentration of Golgi (1,2)-mannosidases in the ER is low, but can be 
increased by their over-expression which accelerates ERAD, indicating that in the ER 
even Golgi mannosidases are involved in glycoprotein trimming (Hosokawa, et al., 
2007). For the EDEMs it is not fully understood, whether they act only as cofactors of 
ERManI, or if they are true mannosidases (Benyair, et al., 2011).  
1.5.3.3. Recognition of substrates by the ERAD machinery 
The glycans generated by trimming actions of various glycosidases are recognized by 
crucial ERAD protein factors like Yos9 in yeast or OS-9 and XTP3-B in mammals. 
These factors deliver the misfolded proteins to the ERAD pathway (Bagola, et al., 
2011).  Yos9 is a lectin-like protein with a mannosidase receptor homology (MRH) 
domain. It is assumed that Yos9 acts as a gatekeeper by scanning the glycoproteins 
and allows only Man7GlcNAc2 proteins to enter the ERAD pathway (Stolz & Wolf, 
2010). However, beside the proofreading function, Yos9 also associates with the 
membrane embedded ubiquitin ligase complex Hrd1p-Hrd3p (Hosokawa, et al., 
2010) and BiP (Vembar & Brodsky, 2008).  Hrd1p is a prototypical ERAD E3 ubiquitin 
ligase. These proteins are the central organizers of all ERAD pathways (see figure 12). 
Hrd3 can bind misfolded proteins independently of Yos9. This binding is not due to 
recognition of the characteristic glycans, but due to the binding of hydrophobic 
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protein patches. Hrd3 is most probably necessary to bind non-glucosylated misfolded 
proteins and deliver them to the ERAD pathway (Stolz & Wolf, 2010). The function of 
E3 ubiquitin ligases will be discussed later in detail.  
1.5.3.4. Retrotranslocation: identity of the channel 
In a not fully understood mechanism, the ERAD machinery translocates the misfolded 
proteins into the cytosol (a process termed retrotranslocation), where they are 
eliminated by proteolysis (Stolz & Wolf, 2010). It is still speculated about the nature 
of the channel that allows the substrate to leave the ER lumen, and about the driving 
force for the directional transport (Bagola, et al., 2011). Many studies implicate that 
retrotranslocation into the cytoplasm depends on the Sec61 channel, which is known 
to be necessary for the forward translocation (from cytosol into the ER lumen). In 
fact, mutations in the SEC61 gene reduce the proteasome binding to the channel. It 
has, however, thus far not been experimentally demonstrated that Sec61 alone 
supports the retrotranslocation (Ng, et al., 2007), but this has not been established 
yet (Benyair, et al., 2011). There are also alternative protein candidates for the 
retrotranslocation channel, like the derlin family (Vembar & Brodsky, 2008). Another 
hypothesis implies a non-protein dependent retrotranslocation mechanism: it was 
found that ER stress stimulates lipid droplets formation, which transports the 
misfolded proteins from the ER to the cytosol (Fei, et al., 2009). However, this 
hypothesis has been refuted by a recent study in which it was shown that the droplet 
formation is dispensable for the dislocation of ERAD substrates (Olzmann & Kopito, 
2011).  Sec61 is the only ER protein with the obvious ability to transport proteins 
across the membrane, and therefore it is reasonable to assume that it can promote 
translocation in both directions. It is also known that some proteins are 
retrotranslocated independently of Sec61 (Bagola, et al., 2011).  
Prior to the degradation in the cytosol, most misfolded proteins are first 
ubiquitinated. For this process the actions of E1 ubiquitin-activating enzymes, E2 
ubiquitin-conjugating enzymes and E3 ubiquitin ligases are necessary (Vembar & 
Brodsky, 2008). However, the polyubiquitination of ERAD substrates is also a 
prerequisite for their retrotranslocation into the cytosol. It has been shown that 
mutant ubiquitin variants cause accumulation of ERAD substrates in the ER. The 
function of polyubiquitination for the retrotranslocation is still not fully understood, 
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but probably the ubiquitination is necessary to recruit factors that facilitate the 
retrotranslocation of the misfolded proteins (Bagola, et al., 2011). However, some 
misfolded proteins do not seem to require polyubiquitination for retrotranslocation, 
and these proteins are found in the cytosol when the proteasomes are inhibited. This 
is unusual for most of the ERAD substrates, which remain in the ER if the proteasome 
machinery is abrogated, due to the blocking of retrotranslocation, as it is coupled to 
proteasomal degradation (Benyair, et al., 2011). 
1.5.3.5. Ubiquitination and retrotranslocation 
Ubiquitin is a 76-residue polypeptide, which is highly conserved in all eukaryotes. 
Usually it is covalently linked via its C-terminal glyine to lysine or N – terminal 
methionine residues on the target proteins. It also can be conjugated to other 
ubiquitin molecules, generating polyubiquitinated proteins (Bagola, et al., 2011). 
Dislocation of misfolded proteins to the cytosol is tightly coupled to substrate 
ubiquitination and proteasomal degradation. Many studies have shown that the 
dislocation of misfolded proteins across the ER membrane into the cytosol is 
regulated by luminal, transmembrane and cytosolic complexes build around ER 
ubiquitin ligases (Hebert, et al., 2009).  
The ubiquitination itself is a highly regulated process that includes E1 ubiquitin-
activating enzymes, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligase 
enzymes (Tsai & Weissman, 2011). The E1 ubiquitin-activating enzyme prepares the 
C-terminal glycine of ubiquitin for binding by forming a thioester bond. The activated 
ubiquitin is transferred to the E2 ubiquitin-conjugating enzyme. Finally, the E3 
ubiquitin ligase enzyme transfers the activated ubiquitin from the E2 enzyme to the 
protein substrate (Benyair, et al., 2011). E3 is of central importance, because it is 
necessary for the recognition of substrates, which have to be labeled for degradation, 
and further it catalyzes substrate ubiquitination and organizes the complexes 
necessary for translocation (Smith, et al., 2011).  
Two E3 multi-spanning membrane proteins are implicated in the yeast ERAD 
pathway: Hrd1p and Doa10p. In mammals there is a whole series of E3 proteins 
acting in the ERAD pathway. Both, Doa10p and Hrd1p ligases, contain the catalytic 
RING domains. They have different preferences for unique membrane associated E2 
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enzymes: the Doa10p dependent ubiquitination requires Ubc6 and Ubc7 E2 enzymes, 
whereas Hrd1 requires the Ubc7 E2 enzyme (Vembar & Brodsky, 2008). Hrd3p is a 
yeast dual function protein; it acts as an adaptor protein, which is also part of the E3 
complex, and a regulator of Hrd1p activity. Hrd3p and its mammalian homolog SEL1L 
are the best characterized adaptor proteins that bind to potential ERAD substrates, 
recruiting them to the E3 ligase. Hrd3p is also a regulatory protein that inhibits the 
auto-ubiquitination of Hrd1p. Additionally, a second protein also regulates Hrd1p: 
Usa1p. This protein regulates the oligomerization of Hrdp1, which may be essential 
for its activity (Smith, et al., 2011).  
Another member of the yeast E3 complex is Der1p, a member of the derlin protein 
family. Der1p is a multi-pass transmembrane protein that also acts as an adaptor. 
Further, it is speculated, whether derlins form the translocation channels itself, or if 
they participate in a complex containing the dislocation channel (Hebert, et al., 2009).  
Once the misfolded glycoproteins have become polyubiquitinated, they have to be 
extracted from the membrane into the cytosol. In this process the cell-division cycle-
48 complex (Cdc48) plays an important role in both, yeast and mammals. In yeast, the 
Cdc48 complex is composed of a hexameric AAA ATPase, which is Cdc48, and two 
additional factors: Ufd1 and Npl4. The homolog of Cdc48 in mammals is p97, and the 
homologs for Ufd1 and Npl4 are UFD1 and NPL4 (Vembar & Brodsky, 2008). In some 
cases also the proteasome lid plays a role in this key cytosolic event of substrate 
extraction (Smith, et al., 2011). The Cdc48-Ufd1p-Npl4p complex is involved in many 
cellular processes like cell cycle progression, transcription factor processing and 
homeotypic membrane fusion (Bagola, et al., 2011). Probably it also generates the 
driving force for the protein extraction, due to its AAA-ATPase activity (Gauss, et al., 
2006). Finally, the Cdc48 complex is thought to transport ERAD substrates to the 
cytosol and to prevent their aggregation (Bagola, et al., 2011). The ERAD substrates 
are recruited to the Cdc48 complex by a family of proteins containing an ubiquitin 
regulatory X domain (UBX). The 80-amino acid long UBX domain also regulates the 
activity of Cdc48 and its homolog p97. The main member of this family involved in 
ERAD is Ubx2 in yeast, and Erasin (Ubxd2) in mammals (Benyair, et al., 2011).  
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1.5.3.6. Shuttling to the proteasomes 
Once the proteins are retrotranslocated and ubiquitinated, the cdc48/p97 complex 
recruits a peptide N-glycanase that removes the N-linked glycans (Smith, et al., 2011). 
In some cases, this seems not to be an essential step and in this cases the proteins are 
degraded by the proteasomes while still glycosylated (Benyair, et al., 2011).  
The task of shuffling the misfolded proteins to the proteasome is thought to be 
carried out by proteins that contain an ubiquitin-like domain (UBL) and an ubiquitin-
associated domain (UBA) (Raasi & Wolf, 2007). Two yeast factors in this class are 
Rad23 and Dsk2. However, it is not clear yet, if these factors are just static members 
of the Cdc48 complex, or if they act as mobile escorts (Vembar & Brodsky, 2008).  
1.5.3.7. Substrate recognition by the proteasome 
The mammalian proteasome is a 26S multisubunit enzyme consisting of the catalytic 
core particle (20S complex) and the regulatory particle (19S complex) (Benyair, et al., 
2011). The regulatory particle (RP) contains ATPase domains, which provide energy 
for degradation, and an ubiquitin binding subunit. The regulatory activities of the RP 
are: i) recognition of the misfolded, retrotranslocated proteins, ii) removal of the 
polyubiquitin chain, iii) unfolding the proteins and iv) driving the protein to the 
protease chamber of the catalytic particle (Raasi & Wolf, 2007).  
1.5.4. Unfolded protein response 
If for some reason the ERAD pathway is overloaded, the retrotranslocation of 
unfolded or misfolded proteins is delayed, and they can accumulate in the ER. This 
accumulation leads to the ER stress which initiates the unfolded protein response 
(Kaser, et al., 2011). Cells usually respond to stressful conditions by changing their 
expression pattern. As a consequence, molecular chaperones are usually 
overexpressed which is essential for folding and oligomerization of polypeptides. In 
stressful situations, these proteins facilitate stabilization in a sense that they try to 
refold the misfolded proteins (Flores-Diaz, et al., 2004).  
Generally, the UPR represents a collection of highly conserved signaling pathways 
which collectively monitor the conditions in the ER. If due to the UPR the cells fail to 
establish a homeostasis, the UPR is able to induce apoptosis (Walter & Ron, 2011).  
As already mentioned, the UPR is a highly conserved biological process. In yeast, the 
UPR is managed by the IRE1-Hac1p pathway. The key players in this pathway are the 
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Figure 13. Three UPR branches in mammalian cells (Walter & Ron, 2011).  
Each pathway uses a different mechanism of signal transduction: ATF6 by regulated proteolysis, PERK by translational 
control, and IRE1 by nonconventional mRNA splicing (Walter & Ron, 2011). 
bifunctional transmembrane inositol requiring enzyme 1 (IRE1) and a transcription 
factor named Hac1p. IRE1 acts as a sensor molecule and a ribonuclease. If misfolded 
or unfolded proteins accumulate in the ER, IRE1 is activated by oligomerization in the 
ER membrane. When activated, IRE1 displays an endoribonuclease activity in the 
cytosol, which cleaves the Hac1p transcript. This splice product encodes a 
transcription factor which moves to the nucleus and regulates the expression of 
specific genes, which are necessary for the maintenance of homeostasis (Kaser, et al., 
2011).     
1.5.4.1. Mammalian UPR 
In mammalian cells, the UPR is more complex. Until today, three different branches of 
the UPR have been identified. These branches operate in parallel and each of them is 
defined by a class of transmembrane factors (Walter & Ron, 2011). The branches are 
mediated by three ER membrane receptors: i) activating transcription factor 6 
(ATF6), ii) double-stranded RNA-activated protein kinase-like endoplasmic reticulum 
kinase (PERK) and iii) inositol requiring kinase 1 (IRE1) (Chakrabarti, et al., 2011). 
30 
 
Similar to the yeast UPR, the activated branches produce transcription factors which 
regulate the expression of some UPR target genes (Walter & Ron, 2011). The three 
UPR branches are illustrated in figure 13.  
BiP (Grp78), which is a critical member of the Hsp70 family, is a chaperone that 
recognizes and binds to misfolded and unfolded proteins. It does not only act as a 
folding chaperone, but it also regulates the activation of three different UPR branches. 
In absence of ER stress (low levels of unfolded/misfolded proteins in the ER), BiP is 
bound to ATF6, PERK and IRE1. Under these conditions, the three UPR transducers 
are inactivated (Chakrabarti, et al., 2011).  BiP physically inhibits the dimerisation of 
Ire1 and PERK, and in this way it inhibits their activity. Accumulation of unfolded or 
misfolded proteins in the ER lumen disturbs the BiP-Ire1 and BiP-PERK interaction. 
As a consequence, the dimerisation and activation of PERK/Ire1 molecules are 
permitted and the UPR pathways are activated. BiP also regulates the activity of 
ATF6, but in a different way: it prevents the movement of ATF6 to the Golgi. However, 
increased levels of unfolded or misfolded proteins prevent the interaction between 
BiP and ATF6, allowing ATF6 to move to the Golgi and activate the third UPR pathway 
(Diehl, et al., 2011).  
ATF6 pathway 
ATF6 is initially synthesized as an ER transmembrane protein. While bound to BiP, it 
remains inactivated in the ER membrane. However, upon accumulation of misfolded 
or unfolded proteins, it is released from BiP and escapes to the Golgi via transport 
vesicles. In the Golgi, it is sequentially processed by the site-1 (S1P) and site-2 (S2P) 
protease. Afterwards, the cytosolic fragment is released and moves to the nucleus, 
where it acts as a transcription factor which activates, together with other 
transcription factors and co-regulators, the expression of BiP, PDI and Grp94 (Walter 
& Ron, 2011). The ATF6 induced gene expression is also cytoprotective (Chakrabarti, 
et al., 2011). 
PERK pathway 
After dissociation from BiP, upon accumulation of misfolded and unfolded proteins in 
the ER, PERK is activated due to oligomerization and autophosphorylation (Walter & 
Ron, 2011). Further, the activated receptor also phosphorylates the initiation factor 
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Figure 14. A speculative model of IRE1 activation (Walter & Ron, 2011) 
The figure depicts multiple structures of the IRE1 luminal ER stress–sensing domain (A). IRE1 may be activated in 
response to an accumulation of unfolded proteins in the ER lumen (B) (Walter & Ron, 2011) 
eIF2 and the bZIP transcription factor Nrf2 (Schröder & Kaufman, 2005). The 
phosphorylation of eIF2 leads to three downstream effects. In the first place, it leads 
to a global attenuation of translation initiation. As a consequence, the protein import 
into the ER is decreased, and therefore the removal of proteins accumulated in the ER 
is facilitated (Chakrabarti, et al., 2011). However, expression of some specific proteins 
is induced if eIF2 is phosphorylated. ATF4, a transcription factor, is one of these 
proteins. The induced ATF4 positively regulates the expression of cell protective and 
pro-apoptotic factors (Walter & Ron, 2011). 
IRE1 pathway 
IRE1 is a 100 kDa ER transmembrane protein, containing an endoribonuclease and a 
serine-threonine kinase domain. Its N-terminus is located in the ER lumen where BiP 
is bound under normal conditions. However, increasing amounts of unfolded and 
misfolded proteins in the ER remove BiP and allow IRE1 dimerisation (Chakrabarti, et 
al., 2011).  As a consequence of dimerisation, IRE1 autophosphorylates and activates 
itself. The activated IRE1 cleaves the XBP-1 transcript at two specific positions 
removing an intron. This alternative splicing generates a mRNA which is translated to 
XBP-1 which is a transcription factor. It seems that XBP-1 in mammals plays a special 
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role in regulation of lipid biosynthetic enzymes and ERAD components (Walter & 
Ron, 2011). A model of IRE1 activation is shown in figure 14.  
1.5.4.2 UPR induced apoptosis 
In most cases the UPR has cytoprotective effects. However, if UPR fails to establish 
the ER homeostasis, it can induce programmed cell death (apoptosis). The 
mechanisms for UPR induced apoptosis are still poorly understood, but one 
possibility is that the relative timing of the three UPR pathways can shift the balance 
between the cyto-protection and apoptosis (Walter & Ron, 2011). There is also strong 
evidence that Ca2+ release from the ER mediates apoptosis as well as the activation of 
caspases (Diehl, et al., 2011).  
Recent studies indicate that UPR can also induce autophagy, which is a cellular reboot 
mechanism, unlike apoptosis which is a terminal death program (Chakrabarti, et al., 
2011). 
1.5.4.3. Effect of glucose starvation on the UPR 
The N – glycosylation of secretory proteins is an essential step which, as already 
described, is necessary for protein folding (CNX cycle) and the quality control (Wilson 
& High, 2007). However, due to glucose starvation, the level of UDP-Glc which is a 
precursor necessary for protein N – glycosylation is decreased and thus glycosylation 
is disturbed. Similar conditions have been shown to induce the overexpression of 
stress proteins in bacteria, which are required for survival. It has been shown that 
also glucose starvation induces at least one stress protein. However, some studies 
have demonstrated that an UDP-glucose deficiency in mammals causes an 
overexpression of some glucose/oxygen-regulated proteins, independently of the ER 
stress elements (Flores-Diaz, et al., 2004).  
These findings should be seen in the context of the practical part of this diploma 
thesis, that in part was done with mammalian cells which have a defective UDPG:PP, 
and therefore have a permanent low level of UDP-Glc. 
1.6. Diseases of glycosylation 
Diseases of glycosylation are rare inherited disorders known as congenital disorders 
of glycosylation (CDG) (Hennet, 2012) which affect glycoprotein biogenesis (Freeze & 
Aebi, 2005). Nowadays nearly 70 genetic disorders are known to be caused by 
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Gene 
Gene locus 
MIM # 
Function Disease 
Nucleotide – sugar biosynthesis 
PMM2 601785 Phosphomannomutase  (Man-6-P > Man-1-P) PMM2-CDG (CDG-Ia) 
MPI 154550 Phosphomannose Isomerase (Fru-6-P > Man-6-P) MPI-CDG (CDG-Ib) 
GFPT1 138292 Glutamine: fructose-6-phosphate amidotransferase Congenital myasthenic syndrome 
GNE 603284 UDP-N-acetylglucosamine 2-epimerase Herediatry inclusion body myopathy 
GALK 604313 Gal kinase Galactosemia 
GALT 606999 Gal-1-P uridylyltransferase Galactosemia 
GALE 606953 UDP-Gal 4-epimerase Galactosemia 
Dolichol biosynthesis 
DHDDS 608172 Cis-prenol synthase Retinitis pigmentosa 
SRD5A3 611715 Polyprenol reductase SRD5A3-CDG (CDG-Iq) 
TMEM15 610746 Dol kinase TMEM15-CDG (CDG-Im) 
N-glycosylation 
TUSC3/N33 601385 Oligosaccharyltransferase Autosomal recessive mental retard. 
IAP/MAGT1 300715 Oligosaccharyltransferase X – linked mental retardation 
GCS1 601336 α1-2 glucosidase GCS-CDG (CDG-IIa) 
MAN1B1 604346 ER α1-2 mannsidase-I Autosomal recessive mental retard. 
MGAT2 602616 β1-2 GlcNAc-transferase MGAT2-CDG (CDG-IIa) 
B4GALT1 137060 β1-4 Gal-transferase B4GALT1-CDG (CDG-IId) 
ST3GAL3 606494 α2-3 Sia-transferase Autosomal recessive mental retard. 
Table 5. Diseases of glycosylation (Hennet, 2012). 
 
impaired synthesis of glycoproteins (Freeze, et al., 2012). Most disorders are due to 
defects in the N-glycosylation, O-glycosylation or both (Jaeken, et al., 2009). CDGs are 
classified into the type I (CDG-I) and type II (CDG-II) disorders (Freeze, 2007). CDG-I 
are more common (Woods, et al., 2012), and they include all disorders of N-
glycosylation site occupancy, while CDG-II include all other disorders of N-
glycosylation, O- glycosylation and glycolipid biosynthesis (Hennet, 2012).  Most of 
the disorders are caused by autosomal recessive mutations (Jaeken, 2011).  
As the number of known glycosylation disorders is increasing, a new CDG 
nomenclature is applied which was suggested by Jaeken and colleagues (Jaeken, et al., 
2009). The meanwhile established nomenclature focuses on the name of the mutated 
gene followed by the “CDG” abbreviation (Hennet, 2012). A list of gene defects 
responsible for the main disorders is shown in table 5. 
CDGs show a broad clinical spectrum, and they can affect nearly all organs and 
systems. Nowadays, treatment is available only for few CDGs, including MPI-CDG, 
SLC35C1-CDG and PIGM-CDG (Jaeken, 2011). However, defects in the glucosidase I 
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gene (GSC1), ER mannosidase I gene (MAN1B1) and other components of the N – 
glycosylation processing machinery are accompanied with a severe pathology. A 
selection of CDGs is briefly described below.  
1.6.1. PMM2 – CDG 
Phosphomannomutase 2 (PMM2) is a cytosolic enzyme which catalyzes the 
conversion of Man-6-P to Man-1-P (Haeuptle & Hennet, 2009).  Mutations in the 
PMM2 gene (OMIM ID: 601785) represent the most frequent type of CDG with an 
incidence of about 1:50.000, affecting the biosynthesis of N-glycans, O-glycans and 
GPI anchors (Hennet, 2012).  
PMM2 – CDG is mainly associated with psychomotor retardation, developmental 
delay, epilepsy, ataxia and other neurologic symptoms (Haeuptle & Hennet, 2009).  
1.6.1. MPI – CDG 
MPI – CDG is caused by a mutation in the mannose phosphate isomerase (MPI) gene 
MPI (OMIM ID: 154550) (Haeuptle & Hennet, 2009). MPI is necessary for Man-6-P 
generation and a deficiency of MPI results in unoccupied N-glycosylation sites on 
glycoproteins (Sharma, et al., 2011).  
MPI – CDG patients commonly show the following symptoms: diarrhea, vomiting, 
gastrointestinal bleeding, hepatomegaly and hepatic fibrosis (Hennet, 2012).  High 
doses of mannose make this lethal disease treatable (Jaeken, 2011). 
1.6.2. GSC1-CDG 
So far, one case o glucosidase I (GSC1) deficiency was reported (OMIM ID: 601336). 
Due the importance of glucosidase I for N – linked glycoprotein trimming, this 
mutation causes a loss of N-glycan trimming and is accompanied with a severe 
pathology with the following symptoms: dysmorphism, hypotonia. So far no efficient 
therapy is known and the disorder causes death of the affected infants (Hennet, 
2012). 
1.6.3. MAN1B1-CDG 
The MAN1B1 gene encodes ER mannosidase I, an enzyme which is involved in the 
maturation of N-linked glycans in the ER. As described earlier, this enzyme is also 
necessary for the timing and disposal of misfolded proteins through the ERAD 
pathway. However, mutations in this gene cause abnormal trimming and, as a 
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consequence, disorders of the ERAD pathway (OMIM ID: 604346). MAN1B1 – CDG 
patients show intellectual disabilities, such as delayed speech and mild dysmorphic 
features (Hennet, 2012). 
1.7. Truncated versions of ribophorin I as an ERAD substrate 
During this diploma thesis, the ERAD pathway was studied using two truncated 
variants of ribophorin I (see 1.3.2. Ribophorin I).  One version of the truncated 
polypeptide consists of only the 332 N-terminal amino acids (RI332) of the mature 
protein, thus lacking the transmembrane and cytoplasmic domains of wild type 
ribophorin I. Hence, the soluble protein corresponds to most of its wild type luminal 
domain (de Virgilio, et al., 1998).  As RI332 is a misfolded protein, it is targeted to 
ERAD and is rapidly degraded. The second truncated variant used in this study 
contains also the 332 N-terminal amino acids of wild type ribophorin I, but in 
addition harbors a 6HA tag (RI332-6HA) at its C-terminus. This truncated variant is 
also rapidly degraded by the proteasome (Ermonval, et al., 2001), which makes it a 
favorable ERAD substrate model. Using HeLa cell transformants it was shown that 
during the process of RI332 degradation trimming intermediates of the N-linked 
glycan occur and that retrotranslocation of the protein to the cytoplasm and 
degradation by the proteasome are highly coupled processes (Kitzmüller, et al., 
2003).  
The cDNA of both variants of the truncated ribophorin I were inserted into the 
pZeoSV  vector (Invitrogen) during former studies, allowing for a selection of cells 
expressing one of the two truncated proteins in the Chinese hamster fibroblast cell 
lines G3 and QC.      
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2. Materials 
2.1. Chemicals and reagents 
2 - mercaptoethanol (>98%)      Sigma 
Acetic acid (99% – 100%)       AppliChem 
Ammonium Persulfate       Bio Rad 
Bromphenol blue        AppliChem 
CHAPS         Fluka 
CHAPS         Sigma Aldrich 
Complete (Protease inhibitor cocktail tablets)    Roche 
Cysteine         Sigma 
D(+) – Galactose        Sigma 
ddH2O         - 
Developer (G153 B)        AGFA 
Developer (G153)        AGFA 
EN3HANCE         Perkin Elmer 
EtOH 96%         Brenntag 
Fluorescent mounting medium      Dako 
G-418 Sulphate (Geneticin)       Gibco 
G-418 Sulphate (Geneticin)       PAA 
Glycine         AppliChem 
HCl (60%)         Amresco 
Immersion oil        Zeiss 
Isobutanol         Merck 
KCl          AppliChem 
MEM NEAA (non essential amino acids) 100x    Invitrogen 
Methanol (dried, max. 0.003% H2O)     Merck  
Methanol (pure)        Brenntag 
Methionine         Sigma 
Milk powder (low fat)       Maresi 
N, N, N’N’ – Tetramethylethylendiamin (TEMED)   Merck 
NaCl          Sigma 
NEC-811 Protein MW Markers, [14C] methylated    Perkin Elmer 
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NEG-072 Expre35s35s, [35S] Protein Labeling Mix    Perkin Elmer 
Penicillin/Streptomycin (10.000 U/ml/10.000µg/ml)   Gibco 
Precision Plus Protein Standards      Bio Rad 
Protein A Sepharose CL-4B       GE Healthcare 
Rapid fixer (G354)        AGFA 
Sodium Dodecyl Sulfate (SDS)      AppliChem 
TRIS          Amresco 
Triton X 100         Amresco 
Trypsin – EDTA 5% (10x)       Gibco 
Tween 20         Amresco 
 
2.2. Buffers and solutions 
CHAPS lysis buffer  
1% CHAPS         Fulka/Sigma 
4% Complete Protease Inhibitor      Roche 
95% HBS 
 
CHAPS wash buffer 
0,5% CHAPS         Fulka/Sigma 
1% Complete Protease Inhibitor      Roche 
98,5% HBS 
 
Fixation solution 
10% (v/v) Acetic acid       AppliChem 
30% (v/v) Methanol        Brenntag 
ddH2O         - 
 
HBS 
50mM HEPES NaOH pH 7,6       USB 
200mM NaCl         Sigma 
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Immunofluorescence blocking solution 
1% milk powder        Instant 
99% PBS 
 
PBS 
137mM NaCl         Sigma 
2,5mM KCl         AppliChem 
10mM Na2HPO4        Merck 
1,7 mM KH2PO4        Merck 
 
Running buffer 
25mM Tris 
192mM Glycine        AppliChem 
0,1% SDS         AppliChem 
 
Transfer buffer 
25mM Tris 
192mM Glycin        AppliChem 
 
Sample buffer 
50mM Tris          
0,1% Bromphenol Blue       AppliChem 
2% SDS         Amresco 
10% Glycerol         Sigma 
3% β mercaptoethanol       Sigma 
 
SDS wash buffer 
95mM NaCl         Sigma Aldrich 
25mM Tris/HCl pH 7,4       Amresco 
3mM EDTA         Sigma 
1,25% Triton X        Amresco 
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0,2% SDS         AppliChem 
1% Complete Protease Inhibitor      Roche 
 
SDS lysis buffer 
95mM NaCl         Sigma Aldrich 
25mM TrisHCl pH 7,4       Amresco 
3mM EDTA         Sigma 
1% SDS         AppliChem 
4% Complete Protease Inhibitor      Roche 
 
SDS PAGE 10% (for four gels) 
Separation gel 
5,34ml dH2O 
3,33ml solution I 
1,26ml solution IIA 
54µl 20% SDS        Amresco 
5µl TEMED         Merck 
50µl 10% APS        BioRad 
 
Stackig gel 
3,6ml dH2O 
0,75ml solution I 
0,63ml solution II B 
25µl 20% SDS        Amresco 
5µl TEMED         Merck 
25µl 10% SDS        BioRad 
 
Solution I (PAGE) 
30% Acrylamide        USB 
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0,6% Bis acrylamide        USB 
 
Solution IIA (PAGE) 
3M Tris/HCl pH 8,9 
 
Solution IIB (PAGE) 
0,5M Tris/HCl pH 6,7 
 
Triton X-100 buffer (10ml) 
1ml 2M Tris/Maleat pH 6,5       Merck 
10µl 2M CaCl2        Sigma 
400µl Complete Protease Inhibitor     Roche 
140µl Triton X-100        Amresco 
 
Trypsin – EDTA solution 
90% PBS 
10% Trypsin – EDTA (10x)       Gibco 
 
Western blot blocking solution 
5% milk powder        Instant 
94,8% PBS 
0,2 Tween 20         Amresco 
 
 
2.3. Cell culture media   
Growth medium (hamster cells) 
RPMI – 1640 (500ml)       Gibco 
- L-glutamine 
+ D-glucose 
1% Glutamine (200mM)       Gibco 
1% Pen (10.000 U/ml)/ Strep (10.000µg/ml)    Gibco 
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10% Fetal calf serum (FCS)       Gibco 
400µg/ml G418 sulfate (Geneticin)     Gibco 
1,25ml/500ml Zeocin (100mg/ml)     Invitrogen 
 
Growth medium (HeLa cells) 
MEM          Gibco 
Low glucose 
- Glutamine 
7% FCS         Gibco 
1% L-glutamine        Gibco 
1% Pen (10.000 U/ml)/ Strep (10.000µg/ml)    Gibco 
400µg/ml G418 sulfate (Geneticin)     Gibco 
 
High galactose medium (hamster cells) 
RPMI – 1640         Gibco 
+ L-glutamine 
- D-glucose 
1% Glutamine        Gibco 
1mM glucose         Sigma 
5mM galactose        Sigma 
1% MEM NEAA (100x)       Gibco 
1% Pen (10.000 U/ml)/ Strep (10.000µg/ml)    Gibco 
400µg/ml G418 sulfate (Geneticin)     Gibco 
1,25ml Zeocin (100mg/ml)       Invitrogen 
 
High glucose medium (hamster cells) 
RPMI – 1640         Gibco 
+ L-glutamine 
- D-glucose 
1% Glutamine        Gibco 
6mM glucose         Sigma 
1% MEM NEAA (100x)       Gibco 
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1% Pen (10.000 U/ml)/ Strep (10.000µg/ml)    Gibco 
400µg/ml G418 sulfate (Geneticin)     Gibco 
1,25ml Zeocin (100mg/ml)       Invitrogen 
 
Pulse – chase media 
Starvation medium (hamster cells) 
RPMI – 1640         Gibco 
- L-glutamine  
- L-methionine 
- L-cysteine 
- L-cystine 
1% Glutamine        Gibco  
 
Pulse medium (hamster cells) 
Starvation medium 
NEG-072 Expre35s35s, [35S] Protein Labeling Mix  (11 mCi/ml)  Perkin Elmer 
 
Chase medium (hamster cells) 
Growth medium (hamster cells) 
5mM methionine (unlabeled) 
5mM cysteine (unlabeled) 
 
2.4. Cell lines 
During the practical work, mainly hamster cell lines were used. For some 
experiments, HeLa cells were used in order to check antibody reactivity. 
All hamster cell lines originated from a chinese hamster mutant cell line (DonQ), 
described in former studies (Flores-Diaz, et al., 2004). DonQ cells have a recessive 
mutation in the UDP-glucose pyrophosphorylase (UDPG:PP) gene, which was induced 
by chemical mutagenesis (ethyl methanesulfonate). Consequently, these cells have a 
low level of UDP-glucose, and therefore, glucosylation is affected. In further studies, 
DonQ cells were transfected with i) a vector carrying the cDNA of a w/t bovine 
UDPG:PP cDNA, and ii) a empty vector. Thus, two cell lines were generated: i) the G3 
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Primary antibodies 
Name Manufacture Type Recognizes  Host animal Application and dilution 
Anti-BiP C-20 Santa Cruz Polyclonal BiP (GRP78) in ER Goat Western blot (1:600) 
Anti-Calnexin Abcam Monoclonal Calnexin in ER Mouse Immunofluorescence (1:50) 
Anti-Calnexin Ivessa et al.  Polyclonal Calnexin in ER Rabbit 
Immunofluorescence (1:200) 
Western blot (1:10000) 
Anti-Calreticulin Bioreagents Polyclonal Calreticulin in ER Rabbit Western blot (1:2000) 
Anti-RI lum Ivessa et al. Polyclonal Ribophorin I Rabbit 
Immunofluorescence (1:200) 
Pulse – chase (1:10) 
Western blot (1:5000) 
CTR433 Bornens et al. Monoclonal 
CTR433 in Golgi 
apparatus 
Mouse Immunofluorescence (1:40) 
ERGIC-53 Alexis Biochemicals Monoclonal ERGIC Mouse Immunofluorescence (1:1000) 
ERGIC-53 ENZO Monoclonal ERGIC Mouse Immunofluorescence (1:1000) 
ERGIC-53 Santa Cruz Polyclonal ERGIC Rabbit Immunofluorescence (1:50) 
Ero1 - Lα Santa Cruz Monoclonal 
Oxidoreductin-1-Lα 
in ER 
Mouse Immunofluorescence (1:100) 
Giantin Abcam Polyclonal Golgi apparatus Rabbit Immunofluorescence (1:2000) 
HA.11 Covance Monoclonal 
Tagged RI332-6HA 
(HA epitope) 
Mouse 
Immunofluorescence (1:50) 
Pulse – chase (1:30) 
Western blot (1:5000) 
Monoclonal Anti 
α Tubulin 
Sigma Aldrich Monoclonal α tubulin Mouse Western blot (1:15000) 
Rabbit polyclonal 
to LMAN1 
Abcam Polyclonal ERGIC Rabbit Immunofluorescence (1:50) 
Secondary antibodies 
Name Manufacture Host animal Recognizes  Application and dilution 
Alexa Fluor 488  Invitrogen Goat Rabbit antibodies Immunofluorescence (1:200) – green fluorescence 
Alexa Fluor 594 Invitrogen Goat Mouse antibodies Immunofluorescence (1:200) – red fluorescence 
Goat anti rabbit 
(HRP) 
Accurate Chemical  Goat Rabbit antibodies Western blot (1:20000) 
Goat anti mouse 
(HRP) 
Accurate Chemical Goat Mouse antibodies Western blot (1:20000) 
Rat anti goat 
(HRP) 
Accurate Chemical Rat Goat antibodies Western blot (1:50000) 
Table 6. Overview of primary and secondary antibodies 
 
cell line (expressing the w/t UDPG:PP protein) and ii) the QC cell line (carrying only a 
genomic mutant UDPG:PP gene). These cells were obtained from Dr. Stuart E.H. 
Moore (INSERM U773CRB3, Paris, France). A second stable transfection generated G3 
and QC cells carrying the cDNA of a i) short, untagged, ribophorin I (RI – 332), and ii) 
short, HA tagged, ribophorin I (RI – 332 – 6HA). These short versions of ribophorin I 
lack the transmembrane domain, which makes them soluble. They serve as luminal 
misfolded model proteins.  
Finally, four different cell lines, generated and isolated in former studies, were used 
during the practical work: i) G3-RI332 i) G3-RI332-6HA iii) QC-RI332 and iv) QC-
RI332-6HA. The clones used are designated in the Results section where appropriate. 
2.5. Antibodies 
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Inhibitors 
Name Final concentration Solvent Target  Company 
Deoxymannojirimycin hydrochloride (DMJ) 2mM ddH2O ER mannosidase TRC 
Z-Leu-Leu-Leu-H (ZLLL) 50µM DMSO Proteasome Peptides 
Kifunensine (KIF) 2µg/ml ddH2O ER mannosidase TRC 
Castanospermine (CST) 1mM ddH2O Glucosidases I & II TRC 
Table 7. Overview of the inhibitors and their final concentrations 
 
2.6. Inhibitors (drugs) 
2.7. Equipments 
Acrodisc PF syringe filter (0,8/0,2µm)     Pall 
Analysis scale H110        Sartorius 
Cell culture dishes (100mm x 20mm)     IWAKI 
Cell culture dishes (100mm x 20mm)     TPP 
Cell culture dishes (150mm x 20mm)     IWAKI 
Cell culture dishes (60mm x 20mm)     IWAKI 
Cell culture dishes (60mm x 20mm)     TPP 
Cell cultures test plates (6 well plates)     TPP 
Centrifuge 5418        Eppendorf 
Centrifuge tubes 7 x 20mm       Beckmann 
Confocal microscope LSM 510 Meta     Zeiss 
Cooling centrifuge 1k15       Sigma 
Dispenser          Eppendorf 
Falcon tubes (15ml)        Sarstedt 
Falcon tubes (50ml)        Sarstedt 
Film cassette         Sigma 
Filter paper         Whatman 
Flow hood laminair HB 2448      Holten 
Gel electrophoresis equipment      Bio Rad 
Gel electrophoresis Mini PROTEAN Tetra Cell    Bio Rad 
Gel electrophoresis power supply Power Pac 300   Bio Rad 
Gel dryer Slab SGD 4050       Savant 
Heating block thermomixer 5436      Eppendorf 
Hybod-C extra membranes       Amersham 
Incubator         Binder 
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Luer solo (10ml)        B Braun 
Microscope (inverted) ID03 binocular     Zeiss 
Microscope cover glasses (13mm)      Christine Gröpl 
Microscope ID03        Zeiss 
Microscope LSM Meta 510       Zeiss 
pH – meter         Mettler Toledo 
Saran wrap         Dow Chemical 
Scale E5500S-D1        Sortorius 
Stirrer MR 2000        Heidolph 
Ultracentrifuge OPTIMA – TLX rotor (TLA 100)    Beckmann 
Ultracentrifuge OPTIMA – TLX      Beckmann 
Vacuum pump DIVAC 2,4L       Leybold 
Wax plates         Anutex 
X-ray film Amersham Hyperfilm MP (8x10 in.)    GE Healthcare 
X-ray film X-Omat Blue XB (5x7 in.)     Kodak 
X-ray film X-Omat Blue XB (8x10 in.)     Kodak 
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3. Methods 
3.1. Cell culture 
3.1.1. Preparation of cell culture media 
A number of different cell culture media were prepared, depending on the cell line 
and the approach. For experiments with hamster cells, RPMI 1640 medium was used, 
whereas for experiments with HeLa cells the MEM medium was used. All media were 
stored at 4°C.  
3.1.1.1. Growth RPMI medium (complete) 
The following components were added to a new flask (500ml) of RPMI 1640 (without 
glutamine) medium: 220mg of geneticin was weighted into a tissue plate. Geneticin 
was resuspended in 10ml of the prepared medium, and the geneticin solution was 
sterile filtered into the medium flask. Further, 50ml fetal calf serum (FCS), 5ml 
glutamine, 5ml Pen/Strp and 1,2ml zeocin were added. The medium flask was closed 
and mixed. If the medium was not used up in two weeks, 1% of fresh glutamine was 
added to the medium, due to the instability of glutamine.  
3.1.1.2. Starvation RPMI medium 
To the RPMI 1640 starvation medium (without glutamine, methionine, cysteine and 
cystine) only 1% glutamine was added. However, glutamine was always freshly 
added to the aliquots which were used for the given experiment.  
The antibiotics were not added, due to the fact that cells were only incubated up to 
one hour in the starvation medium.  
3.1.1.3. High & low glucose RPMI media   
The high and low glucose media were prepared out of the RPMI 1640 (without 
galactose and glucose) medium. First, glucose and galactose stock solutions (1M) 
were prepared: the appropriate amounts of glucose and galactose were dissolved in 
ddH2O. The stock solutions were sterile filtered into falcon tubes.  
For the high glucose RPMI medium, the glucose stock solution was added to the RPMI 
1640 (with glutamine, without glucose) medium to obtain a 6mM solution. For the 
high galactose RPMI medium (with glutamine, without glucose), the glucose and 
galactose stock solutions were added to the RPMI medium to obtain a 1mM glucose 
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and 5mM galactose solution. Additionally, non essential amino acids were added to 
the medium, since it was already out of date.  
3.1.1.4. Growth MEM medium 
The growth media for the HeLa cells was prepared as the growth media for hamster 
cells (see 3.1.1.1). However, instead of the RPMI 1640 media, the MEM (low glucose, 
without glutamine) media was used. Additionally, 7% FCS was added, instead of 10%.  
3.1.2. Thawing of cells 
The frozen cells (cryo tubes) which were stored at -80°C or in liquid nitrogen tanks 
were taken out and left on ice. Only one cryo tube at a time was used in further steps, 
while the other cells were still on ice. One cryo tube was thawed in the hand till only a 
small piece of ice was left. At this point 0,5ml of fresh RPMI medium was taken out 
from a falcon tube containing 10ml pre-warmed RPMI medium, and transferred to 
the cryo tube. Further, the same volume was transferred from the cryo tube to the 
falcon. This was repeated for several times, and in the end the whole cryo tube 
content was transferred to the falcon tube.  
The falcon tubes containing 11ml cell suspension (10ml RPMI medium and 1ml cryo 
tube content) were centrifuged at 4°C and 1300 rounds per minute (rpm) for 7 
minutes. The supernatant was discarded and the cell pellets were resuspended with 
4ml pre-warmed RPMI medium. Following to this step, the cells were seeded to a 
60mm tissue plate and incubated at 37° and 5% CO2 over night (o/n). 
On the following day, the cells were examined in the ID03 light microscope (Zeiss). 
Cells which reached a density >50% were split to 100mm plates (see 3.1.3 Cultivation 
of cells). Cells which have grown slowly were left for several days in the 60mm plates, 
but the medium was replaced after two days to remove dead cells and to provide the 
living cells with fresh medium.  
3.1.3. Cultivation of cells 
The cells were cultivated on 100mm tissue plates, and they were split after reaching a 
density of approximately 80%. For splitting, the growth medium was removed and 
the cells were washed with pre-warmed 1x PBS. 10ml of pre-warmed PBS was 
carefully pipetted to the edge of the tissue plate, to avoid rinsing off the cells. This 
washing step was necessary to remove dead cells and the rests of the growth medium 
which could inhibit the activity of trypsin, which was used in the next steps.   
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After the washing step, the PBS was removed and 1ml of pre-warmed trypsin was 
added (trypsin was warmed at room temperature; otherwise it would become active 
at 37°C in the water bath). Trypsin was added to detach the cells from the tissue plate 
surface. The cells were incubated for approximately 4 minutes at 37°C with the 
trypsin solution. During incubation, the efficiency of trypsinisation was examined in 
the light microscope. If the cells were detached, growth medium was added to the 
cells to stop the trypsin activity. Otherwise, the trypsinisation was extended. Further, 
the required volume of cell suspension was transferred into a new tissue plate 
containing 10ml of fresh medium. The splitting ratio depended on the cell density; a 
ratio was chosen which allows the seeding of cells with a density of approximately 
10% in the new plate.  
Finally, the cells were evenly distributed by gentle stirring of the tissue plate. The 
cells were incubated at the standard conditions: 37°C and 5% CO2.  
Alternatively, if the cells were incubated for up to four days and in this time didn’t 
reach the density of at least 50%, the growth medium was changed. The old medium 
was removed and fresh pre-warmed medium was added.  
3.1.4. Freezing of cells (preparation of cryocultures) 
Before freezing of the cells, they were expanded on three 150mm tissue plates 
(alternatively on eight 100mm plates). After the cells reached a density of at least 
80%, they were harvested. The medium was removed and the cells were washed with 
pre – warmed 1x PBS (see 3.1.3. Cultivation of cells). Afterwards, 2ml of trypsin was 
added and the cells were incubated at 37°C for four minutes. The trypsinisation was 
stopped by addition of growth medium and the cell suspension was partitioned into 
falcon tubes. Then the cells were centrifuged at 1300rpm for 7 minutes. The 
supernatant was removed and the cell pellets were resuspended in ice cold FCS - 10% 
DMSO: for each 150mm plate 5ml of this solution were used. The resuspended cells 
were aliquoted to cryotubes: 1ml/cryotube. Finally, the cryotubes were set into a 
freezing box which was stored for 24 hours at -80°C. The freezing box allowed a 
stepwise temperature decrease of 1°C per minute. After this period, the cells were 
transferred to storage boxes which were kept in liquid nitrogen tanks.  
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3.2. Screening for stable ERAD substrate expression 
Screening for the ERAD substrate (RI-332 and RI-332-6HA) expression  was done by 
pulse chase experiments, followed by immunoprecipitation and SDS-PAGE. 
3.2.1. Pulse – chase analysis 
3.2.1.1. Seeding of cells 
Before the pulse – chase analysis, the cells were seeded and incubated for 48 hours in 
6 – well plates. Seven chase time points were done for each experiment, and therefore 
seven 6 – well plates were used; every 6 – well plate for one chase time point. Each 
cell clone was seeded into one well with a density of 40 – 50% confluence. For the 
splitting ratio the effective growth surface was considered, and therefore following 
formula was used: 
                        
                        
    
The effective growth surface in each well of the 6 – well plate is 8x smaller as in the 
100mm tissue plate, therefore the factor “8” was used. The splitting procedure is 
described in 3.1.3 Cultivation of cells.  
3.2.1.2. Starvation phase 
After the incubation period of 48 hours, the cell density was estimated under the 
microscope. Cells with a density of at least 80% confluence were used in further 
steps. Otherwise, the growth medium was changed and the cells were incubated for 
another 24 hours. 
The growth medium was aspirated and the cells were briefly washed with pre-
warmed PBS. After the PBS was removed, 1ml of pre-warmed starvation medium was 
added to each well. The cells were incubated for 30 minutes at 37°C and 5% CO2.  
3.2.1.3. Pulse phase 
Following to the starvation phase, the medium was aspirated and 0,8ml of pulse 
medium was added to each well. The cells were incubated at 37°C and 5% CO2 for 
exactly 15 minutes in order to label all proteins with [35S] methionine and [35S] 
cysteine, which were synthesized during this period. 
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3.2.1.4. Chase phase  
Subsequent to the pulse phase, the medium was removed separately, and to each well 
1ml of chase medium was added. Then the cells were incubated under the conditions 
described previously for several time periods; 5’, 15’, 30’, 45’, 60’, 75’ and 90’. Each 
incubation period was terminated by transferring the appropriate 6 – well plate to ice 
and keeping it in the cold room for at least 10 minutes. All further steps were 
performed on ice. 
3.2.2. Cell lysis 
After a short incubation period on ice, the cells were used for cell lysis. For this 
purpose, the medium from each well was removed with an adjustable, air-
displacement pipette, and 1ml ice cold 1x PBS was added to each well.  Then the 6 – 
well plate was gently pivoted and the PBS was again removed with a displacement 
pipette. 150µl of SDS lysis buffer was added to each well, while the plate was still on 
ice. Next, the cells were scraped using a rubber policeman and collected to labeled 
Eppendorf tubes which were also kept on ice. Afterwards, another 150µl SDS lysis 
buffer was added to the wells, and the same procedure was repeated to finally obtain 
a total volume of 300µl in each Eppendorf tube. 
Once the lysates of all 6 – well plates were collected to the Eppendorf tubes, they 
were sonicated (maximum power and constant) for few seconds. Then the cell lysates 
were heated for 3’ at 90° in a heating block.  
After the boiling period, 1ml of ice cold SDS wash buffer was added to each Eppendorf 
tube and after gentle mixing the cell lysates were left on ice for few minutes to cool 
down. Then the cell lysates were centrifuged at 4°C and 14.000rpm for 12 minutes. 
Finally, 1.2ml of the supernatants was transferred to new Eppendorf tubes and the 
cell lysates were further used for immunoprecipitation.  
3.2.3. Immunoprecipitation 
Following to cell lysis, the lysates were used for immunoprecipitation. For this 
purpose, the lysates were incubated with the RI antibody and protein A sepharose 
beads. 
3.2.3.1. Protein A sepharose beads preparation 
The appropriate amount of protein A sepharose beads was weighed and distributed 
to two Eppendorf tubes. The beads were allowed to swell by addition of 1ml SDS 
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wash buffer to each tube, followed by 30’ incubation at 4°C while turning on a 
rotating wheel. Afterwards, the beads were washed: they were centrifuged at 8000 
rpm for 3’, and the supernatant was discarded. The pellets were resuspended with 
1ml SDS wash buffer followed by 10’ incubation at the same conditions as before. 
This washing step was repeated two times, and finally the beads were resuspended in 
the appropriate amount of SDS wash buffer: 12,5µl wash buffer per 1mg previously 
weighed beads. The beads were kept at 4°C before use. 
3.2.3.2. Antibody preparation 
For immunoprecipitation αRI polyclonal antibodies (RI lum) were used. They were 
prepared by 1/10 dilution with SDS wash buffer. The diluted antiserum was also kept 
at 4°C till use. 
3.2.3.3. Immunoprecipitation 
35µl of the prepared beads (see 3.2.3.1. Protein A sepharose beads preparation) and 
30µl of diluted αRI antiserum (see 3.2.3.2. Antibody preparation) were added to the 
cell lysates (see 3.2.2. Cell lysis). The cell lysates were incubated together with the 
beads and antibodies for at least 14h (alternatively over weekend) at 4°C while gentle 
turning on a rotating wheel.  
After the incubation period, the beads were precipitated. To this, the cell lysates were 
centrifuged for 3’ at 13.000 rpm and the supernatant was discarded. Following to 
this, the beads were washed three times with 1ml SDS washing buffer each, and two 
times with 1ml PBS each in the same way. By discarding the supernatant in the last 
PBS washing step, the precipitates were ready to be processed for SDS – PAGE.  
3.2.4. SDS PAGE 
After processing of the precipitates with sample buffer (see 3.2.4.2. Sample 
preparation and loading), they were loaded on a 10% polyacrylamide gel and finally 
visualized on X-ray films. The procedure is described below. 
3.2.4.1. Preparation of polyacrylamide gels 
First the separation gel solution was prepared. To this, the components (see 2.2. 
Buffers and solutions) were pipetted to a 50ml falcon tube. After every pipetting step, 
the solution was gently mixed while avoiding foaming. Then, 10% APS (10% APS was 
stored at -20°C: once used, it was stored at 4°C for max. two weeks) and TEMED were 
added to the gel solution, and again the solution was gently mixed. Finally, this 
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solution was pipetted to the assembled and cleaned Mini PROTEAN 3® System (total 
height of the separation solution was 5.5cm). After it was ensured that the system 
was tight and that the solution was not leaking out, the separation gel solution was 
covered by iso-butanol.  
The polymerization of the separation gel typically lasted about 20 minutes (if fresh 
APS was used) and the end of polymerization was noticed by the formation of a third, 
aqueous phase between the gel solution and iso-butanol. After polymerization, the 
iso-butanol was replaced by water in order to remove any iso-butanol residue. This 
washing step was done twice. Finally, the remaining water was absorbed by filter 
paper.  
The stacking gel solution was prepared analogously to the separation gel and 
pipetted on the polymerized separation gel. The comb was inserted into the stacking 
gel and the gel was left to polymerize.  
3.2.4.2. Sample preparation and loading 
The sample buffer (see 2.2. Buffers and solutions) was completed by addition of 2 – 
mercaptoethanol just before use (because 2 – mercaptoethanol is instabile). 20µl of 
the completed sample buffer was added to each sample (see 3.2.3.3. Precipitation). 
Then the samples were incubated for 3’ at 95°C followed by short centrifugation. At 
this point the samples were ready for loading to the gel, and they were not kept on ice 
anymore.  
The outermost slots of each gel were loaded with sample buffer. One slot of each gel 
was loaded with the NEC-811 protein MW marker and the remaining slots were 
loaded with 17µl samples from each chase time-point. 
3.2.4.3. Gel electrophoresis 
Once loaded with samples, the gels were connected to the power supply. The 
electrophoresis was performed at constant 90V for approximately 2 hours, i.e. till the 
sample buffer reached the end of the gel. 
3.2.4.4. Gel fixation and enhancing 
After electrophoresis, the Mini PROTEAN 3® System was dismounted and the 
stacking gel was removed. The separation gel was carefully transferred to a container, 
containing the fixation solution. After 30 minutes of fixation while shaking, the 
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fixation solution was exchanged by the EN3HANCE solution and the gels were 
incubated for another 30 minutes while shaking. Then the EN3HANCE solution was 
discarded separately and the gels were gently washed with tap water. Afterwards, the 
tanks containing the gels were filled with water and incubated for another 20 
minutes while shaking.  
3.2.4.5. Gel drying 
The washed gels were transferred to wet filter papers, and the filter papers were 
positioned on the gel dryer and covered by saran wrap. Then the dryer was 
assembled and the gels were dried for approximately 40 minutes at 80°C. After a cool 
down for 10 minutes, the gels were ready for fluorography. 
3.2.5. Fluorography 
The gels which were attached to the filter papers after drying were adjusted to 
appropriate film cassettes together with X – ray films in the dark room. The 
assembled and closed cassettes were incubated at -80°C for at least 12 hours. After 
this exposure time, the cassettes were left for about one hour at room temperature in 
order to warm up. Then the cassettes were opened in the dark room and the X – ray 
films were developed. 
3.3. Half life determination of the ERAD substrates RI332 and RI332-6HA 
In order to determinate the half life times of RI332 and RI332-6HA, a similar 
procedure was applied as described in 3.2. Screening for stable ERAD substrate 
expression. The deviations from the procedure are described below. 
3.3.1. Pulse chase analysis 
In order to prepare cells for the pulse chase analysis, the QC clones were seeded to 
the 6 – well plates at a density of 40%. The G3 clones were seeded at a density of 
50%. This was done due to the fact that the QC cells had a faster growth rate. After an 
incubation period of two days at 37°C and 5% CO2, the cells typically reached a 
density of approximately 90% which was optimal for further experiments.  
Unlike the pulse chase analysis for screening studies described in 3.2.1. Pulse – chase 
analysis, in the half life determination studies the cells were additionally incubated in 
the presence of drugs/inhibitors (see 2.6. Inhibitors). In these cases, a pre-incubation 
of the cells was done with the appropriate inhibitor, prior to the starvation phase. 
54 
 
Also the starvation, pulse and chase phases were done in presence of the appropriate 
inhibitor.  
3.3.1.1. Pulse chase with drugs 
Deoxymannojirimycin (dMJ) was supplied in 10mg packages. To obtain a 50mM 
stock [=25x], the powder content was dissolved in sterile ddH2O. This was done 
under sterile conditions. The dMJ stock was stored at -20°C. For the half life 
determination of the ERAD substrates, a final concentration of 2mM was used.  
For pulse chase with dMJ, five chase time points were done: 5’, 30’, 60’, 75’ and 90’. 
Therefore, the following volumes of media were prepared in falcon tubes: 
 Pre-incubation medium (1ml/well): 20,5ml complete medium + 820µl of 
dMJ stock 
 Starvation medium (0,8ml/well): 16,5ml starvation medium + 660µl of dMJ 
stock 
 Pulse medium (0,8ml/well): 16,5ml starvation medium + 660µl of dMJ 
stock + 440µl NEG-072 Expre35s35s protein labeling mix 
 Chase medium (1ml/well): 20,5ml complete medium + 820µl stock of dMJ 
stock + 205µl Met + 205µl Cys 
The total amount of inhibitor was approximately 3ml (of the stock solution) for each 
set of experiments.   
Kifunensine (KIF) was supplied in 1mg packages. The powder was dissolved in 
warm, sterile ddH2O to obtain a 500x stock [1mg/ml]. The stock solution was kept at 
-20°C. For the pulse chase analysis, a final concentration of 2µg/ml was used. In case 
of KIF, seven chase time points were done as with controls (in the absence of the 
drugs): 5’ – 90’. The media were prepared as follows: 
 Pre-incubation medium (1ml/well): 29ml complete medium + 58µl KIF 
stock 
 Starvation medium (1ml/well): 29ml starvation medium + 58µl KIF stock 
 Pulse medium (0,8ml/well): 23,5ml starvation medium + 47µl KIF stock + 
600µl NEG-072 Expre35s35s protein labeling mix 
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 Chase medium (1ml/well): 29ml complete medium + 58µl KIF stock + 290µl 
Met + 290µl Cys 
Total amount of used KIF stock was 221µl for each set of experiments.  
5mg of Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (ZLLL) was dissolved in 1,05ml 
DMSO to obtain a 10mM ZLLL stock [=200x]. The ZLLL stock was stored at -20°C. For 
the pulse chase analysis, a final concentration of 50µM was diluted out of the stock 
solution.  
As for dMJ, only five chase time points were done with ZLLL: 5’, 30’, 60’, 75’ and 90’. 
Therefore, the media were prepared as follows: 
 Pre-incubation medium (1ml/well): 20,5ml complete medium + 102,5µl of 
ZLLL stock 
 Starvation medium (1ml/well): 20,5ml starvation medium + 102,5µl of 
ZLLL stock 
 Pulse medium (0,8ml/well): 16,5ml starvation medium + 82,5µl of ZLLL 
stock + 440µl NEG-072 Expre35s35s protein labeling mix 
 Chase medium (1ml/well): 20,5ml complete medium + 102,5µl stock of 
ZLLL stock + 205µl Met + 205µl Cys 
For each pulse chase analysis, 390µl of the ZLLL stock was used. 
Castanospermine (CST) was delivered in 10mg packages. The content was dissolved 
in 1ml sterile ddH2O to obtain a 52,9mM stock solution [=52,9x]. Like all other drugs, 
the CST stock solution was kept at -20°C. For the pulse chase analysis, all chase time 
points were done as with controls. The media were prepared as follows: 
 Pre-incubation medium (1ml/well): 29ml complete medium + 549µl CST 
stock 
 Starvation medium (0,8ml/well): 23ml starvation medium + 435µl CST 
stock 
 Pulse medium (0,8ml/well): 23ml starvation medium + 435µl CST stock + 
600µl 35S NEG-072 Expre35s35s protein labeling mix 
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 Chase medium (1ml/well): 29ml complete medium + 549µl CST stock + 
290µl Met + 290µl Cys 
All further steps including cell lysis, immunoprecipitation, and SDS-PAGE were done 
in the same way as described in 3.2. Screening for stable ERAD substrate expression. 
The developed X-ray films were analyzed with a densitometer to allow precise half 
life determination of the ERAD substrates. 
3.3.2. Densitometry 
The Fusion-FX7 imager was used for scanning of the developed X – ray films. To this, 
the films were placed into the imager which was operated with the Fusion-CAPT-
Software. 
After the films were set in the imager, the film was focused by the “autofocus” option 
in the software. Then the films were exposed for 0.4 seconds to UV light and then the 
images were captured. The images (with .tiff extensions) were further analyzed with 
the ChemiImager 4400 software. 
The figures were analyzed by the “Spot denso” option which is found in “Analysis 
tools”. Because the bands were dark, the option “invert” was used. Each band was 
circumscribed by the rectangle tool. Afterwards, for each lane, i.e. for each chase time 
point slot, a background was defined by the background rectangle tool. Then the two 
rectangles in each lane (one defining the endogenous ribophorin I and the second 
defining the soluble truncated ribophorin I) were linked to the appropriate 
background rectangle tool.  
The raw data were copied to Microsoft Excel 2007 in which the analysis was 
continued. The coefficients were calculated of each soluble truncated ribophorin I and 
its corresponding endogenous ribophorin I (both in the same chase time point lane). 
With other words, each soluble ribophorin was normalized with its corresponding 
endogenous ribophorin I. The coefficient of the soluble ribophorin at time point 5’ 
was set as 100%. The soluble ribophorins of the different time points were related to 
the first one (5’).  
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For each clone an exponential regression (first order kinetics) was calculated on the 
results of each pulse chase experiment. This regression generated two formulas with 
y being the relative amount of soluble ribophorin after a certain chase time x (e.g.): 
                         
             
The first formula was used for the calculation of the half life. To this, the positive 
exponent (in this case: 0,01472) was applied to following formula: 
     
     
                 
 
So in the given example: 
     
     
       
              
The second formula gave information about the curve progression. The progression 
was better the closer the value was to 1. In the case of the sample, the progression 
was almost ideal.  
3.3.3. Restoring of the wild type phenotype in QC cells 
In order to restore the G3 wild type phenotype in the QC cell lines, the cells were 
cultivated in high galactose medium. Subsequent to the high galactose cultivation, 
pulse chase analysis and all further steps described earlier were done to estimate the 
half life of the soluble truncated ribophorins. The preparation of high glucose and 
high galactose media is described in 3.1.1.3. High & low glucose RPMI media. 
3.3.3.1. Pulse chase analysis 
Different from the earlier described pulse chase analysis, the cells were seeded and 
cultivated for 48 hours in the high galactose and high glucose media in parallel. After 
this period, the cell density was estimated in the light microscope. If the minimal cell 
density of 80% was reached, the experiment was continued. The starvation phase 
(30’) was performed in methionine free RPMI medium with and without galactose 
(5mM), respectively. The same was true for the pulse phase (15’) except that the 
labeled methionine was added to both media. Apart from these deviations, the pulse 
chase analysis and all following steps (i.e. cell lysis, immunoprecipitation, SDS PAGE 
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and densitometry) were performed as described in 3.2. Screening for stable ERAD 
substrate expression and 3.3.2. Densitometry.  
3.3.3.2. Cell visualization 
QC cells were cultivated in 100mm tissue plates with the high galactose medium for 
seven days in order to restore the wild type morphology. During the cultivation, the 
cells were split every time they had reached a density of more than 90%. On the 7th 
day images of the cells were taken in the microscope. 
3.4. Analysis of ERAD substrate – calnexin association  
In order to analyze the interaction between calnexin and the ERAD substrates (RI332 
and RI332 – 6HA), the pulse chase protocol was modified. Accordingly, co – 
immunoprecipitation was done. Finally, SDS PAGE was performed and the gels were 
analyzed by densitometry. 
3.4.1. Pulse chase analysis 
For the purpose of the calnexin – ERAD substrates interaction analysis, only two 
chase time points were chosen: 5’ and 60’. For both chase points three wells of the 6 – 
well plates were seeded with each of the four clones. After an incubation period of 48 
hours, the cell density was estimated. Cells with a minimal density of 80% were 
further processed. After a standard starvation phase for 30’, the pulse phase was 
done for 60’ (instead of 15’). Finally, the cells were incubated in the chase phase for 5’ 
and 60’ minutes, respectively.  
3.4.2. Cell lysis 
One well of each clone was used for the SDS lysis already described previously 
(stringent lysis), while the two remaining wells were used for a more gentle lysis 
method (non – stringent lysis; see 3.4.2.1. Non stringent lysis (CHAPS)). In order to 
perform the stringent lysis, the procedure described in 3.2.2. Cell lysis was followed, 
whereas the non – stringent lysis was different. 
3.4.2.1. Non stringent lysis (CHAPS) 
Two wells of each clone were washed with ice cold PBS. Next, 300µl of the CHAPS 
lysis buffer (see 2.2. Buffers and solutions) was added to each well. The cells were 
scraped and collected in labeled Eppendorf tubes which were kept on ice. Afterwards, 
additional 300µl of the CHAPS lysis buffer was added to the same wells, and again the 
cells were scraped and collected in the appropriate Eppendorf tubes. The collected 
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cells (600µl in total) were kept on ice for 30’. After the incubation period, the cell 
lysates were centrifuged for 10’ at 4°C and maximum speed. Subsequent to the 
centrifugation step, a pre-cleaning was performed by transferring 570µl of the cell 
suspensions to new Eppendorf tubes and adding of 30µl protein A sepharose beads 
(the beads were prepared as described in 3.2.3.1. Protein A sepharose beads 
preparation, but with CHAPS wash buffer instead of SDS wash buffer) to each tube. In 
order to finish the pre-washing step, the eppendorf tubes were incubated for 30’ at 
4°C and while rotating, followed by 5’ centrifugation at maximum speed. The 
supernatant was used for the co – immunoprecipitation. 
3.4.2.2. Co – immunoprecipitation 
The supernatants of each clone were collected to obtain a total volume of 1140µl. 
Afterwards, the lysates were aliquoted to four Eppendorf tubes: 200µl to two tubes 
(=400µl) and 350µl to the other two tubes (=700µl). The two Eppendorf tubes of each 
clone containing 200µl solution were used for only one immunoprecipitation, while 
the other two tubes were used for two consecutive immunoprecipitations. However, 
30µl of protein A sepharose beads was added to each tube. Then 30µl of αRI 
polyclonal antibody (RI lum; 1:10 dilution) was added to one 200µl and one 350µl 
tube, while 30µl of αcalnexin polyclonal antibody (1:10 dilution) was added to the 
other two tubes (200µl and 350µl). All samples were incubated o/n at 4°C while 
rotating. 
Following to the o/n incubation, the samples were washed with CHAPS wash buffer. 
This was done in the following manner: the samples were centrifuged for 3’ at RT and 
8000 rpm. Afterwards, the supernatant was discarded and the pellets were 
resuspended in 1ml chaps wash buffer. Then the samples were rotated for 10’ at 4°C. 
The same procedure was repeated two more times, and a third time with HBS instead 
of the CHAPS wash buffer.  
After the washing steps, the samples which were used for only one 
immunoprecipitation were resuspended in fresh sample buffer, and afterwards they 
were frozen at -20°C where they were kept o/n. The samples which were intended 
for a co – immunoprecipitation were processed as follows: the samples were 
centrifuged and the supernatant (mainly HBS) was discarded. The pellets were 
resuspended in 150µl SDS lysis buffer and were incubated for 5’ at 95°C. After the 
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samples were boiled up, they were centrifuged at 8000rpm for 3’. Subsequently, the 
supernatant was transferred to new Eppendorf tubes. Another 150µl SDS lysis buffer 
was added to the old samples in order to repeat the boiling step. Again the samples 
were centrifuged and the supernatants were collected in the appropriate tubes. Then 
1ml of SDS wash buffer was added to 300µl of each sample. Afterwards, 30µl of 
protein A sepharose beads (prepared in SDS wash buffer) was added to each sample. 
Finally, 30µl of αRI polyclonal or αcalnexin polyclonal antibodies (both diluted 1:10) 
were added to the samples as follows: the αRI antibody was added to the samples 
which were previously immunoprecipitated with αcalnexin antibodies, and the 
αcalnexin antibodies were added to the samples which were previously 
immunoprecipitated with αRI antibodies. All samples were incubated over night 
while rotating at 4°C.  
After the incubation period, the samples were washed with SDS wash buffer and PBS 
as already described. Then 20µl fresh sample buffer was added and all samples 
(including the stringent and non – stringent samples from the day before) were 
boiled at 95°C for 3’. Finally, the samples were ready for loading on the polyacrylamid 
gels.  
3.4.2.3. SDS PAGE and densitometry 
SDS PAGE was performed as described earlier. However, two different exposure 
times were performed for each gel. A short exposure time of 12-24 hours, and a long 
exposure time of 3-4 weeks. The films were analyzed with the ChemiImager 4400 
software as already described.  
3.5. Intracellular localization of RI332 and RI332-6HA 
The two ERAD substrates were localized with immunofluorescence using antibodies 
for three different compartments: ER, ERGIC and Golgi. For this purpose, the cells 
were grown on cover slips (CS) and stained with the appropriate antibodies. 
3.5.1. Seeding of cells 
The cells were seeded on sterile CSs. In order to do so, sterile CSs were supplied in 
100mm tissue culture plates. Afterwards, 10ml of pre-warmed medium was added to 
the plates paying attention that the CSs stay on the ground of the plates, i.e. that they 
do not swim in top of medium. Then, cells were split into the plates containing CSs 
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Combinations with αRI antibodies 
RI polyclonal (1:200) (RI, RI332 and RI332-6HA marker) with CALNEXIN monoclonal (1:50) (ER marker) 
RI polyclonal (1:200) (RI, RI332 and RI332-6HA marker) with ERGIC53 monoclonal (1:1000) (ERGIC marker) 
RI polyclonal (1:200) (RI, RI332 and RI332-6HA marker) with CTR433 monoclonal (1:40) (Golgi marker) 
Combinations with αHA antibodies 
HA.11 monoclonal (1:50) (RI332-6HA marker) with CALNEXIN polyclonal (1:200) ( ER marker) 
HA.11 monoclonal (1:50) (RI332-6HA marker) with ERGIC53 polyclonal (1:50) (ERGIC marker) 
HA.11 monoclonal (1:50) (RI332-6HA marker) with GIANTIN polyclonal (1:2000) (Golgi marker) 
Table 8. Antibody combinations used for the localization experiments 
 with a total density of about 10 - 20%. The cells were incubated for 48 hours at 37°C 
and 5% CO2. 
3.5.1.1. Incubation with drugs 
Additionally, the cells were also incubated with drugs in some experiments. For this, 
the cells were seeded just as described in 3.5.1. Seeding of cells, but after 34 hours 
incubation, the growth medium was removed and new medium containing the 
appropriate inhibitor was added (see 2.6. Inhibitors). Then the cells were incubated 
for additional 14 hours at 37°C and 5% CO2. 
3.5.2. Fixation of the cells 
After incubation, the growth medium was discarded and the cells were washed with 
1x PBS. During washing, it was paid attention that the CSs stay on the bottom of the 
dish. PBS was removed and cold methanol (-20°C) was added to the dishes (enough 
methanol to cover all CSs). The cells were incubated for 3’ at -20°C. Then the 
methanol was removed and the cells were briefly washed three times with PBS, and 
additionally incubated for 10’ in PBS while shaking.  
3.5.3. Immunolabeling 
After washing, blocking solution was added to the dishes containing the CSs. The cells 
were incubated with blocking solution for one hour while shaking at RT. Meanwhile, 
the primary antibodies were diluted and kept on ice. Typically, two different 
antibodies were used (one monoclonal and one polyclonal) for staining. However, for 
the analysis of co-localizations, single stainings were done as well.  (see table 8 for 
antibody combinations).  
After the incubation in PBS, 20µl of the diluted antibodies were pipetted on wax 
plates. Then the CSs were put on the drops with the cells facing down. Before 
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applying, the CSs were dripped off by leaning the CS’s edge to a paper towel. The wax 
plate was put into a wet chamber and incubated for one hour at 37°C.  
Afterwards, the CSs were transferred to 6 well plates in order to remove unbound 
antibodies. For the washing steps, blocking solution was pipetted to each well 
containing CSs and the 6 – well plates were incubated for 10’ while shaking. Then the 
blocking solution was discarded and fresh blocking solution was added. Washing was 
repeated three times. After washing, the cells were incubated with the 2nd antibodies. 
Both 2nd antibodies (see 2.5. Antibodies) were prepared in blocking solution at a 
concentration of 1:200. Then the 2nd antibody dilution was portioned per 20µl on the 
wax plate, and the CSs were put on the drops with the cells facing down. The wax 
plate was incubated in the wet chamber for one hour at 37°C. All working steps with 
2nd antibodies were performed under dimmed conditions.  
After this incubation, the CSs were transferred to 6 – well plates in order to be 
washed. Washing was performed as described earlier but with two additional 
washing cycles with PBS instead of blocking solution. Finally, the CS’s were mounted 
on glass slides. Small drops of mounting solution were placed to the glass plates and 
they were covered with the CSs, with the cells facing down. The excess of mounting 
medium was soaked up and the CSs were sealed with nail varnish which was applied 
to the edges of the CSs. The glass slides were stored at 4°C. 
3.5.4. Visualization 
Cells were visualized with the LSM 510 META microscope (Zeiss), and with the help 
of the ZEN 2009 software. Before imaging, adjustment of the microscope was done as 
follows. 
3.5.4.1. Microscope adjustment 
All parameters were adjusted using the ZEN 2009 software. The optic parameters 
were adjusted as follows: the Plan-Apochromat 63x objective was chosen and the 
transmitted light filter was set to 100%. Then the transmitted light fieldstop was set 
to 82.07%. Two different reflectors were used: FSet20 for the red channel and FSet10 
for the green channel.  
Two lasers were turned on: Argon/2 (laser lines [nm]: 458, 477, 488 and 514) and 
HeNe1 (laser line [nm]: 561).  
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In the imaging setup, the “Channel mode” was used and the track was switched after 
every frame. The scan mode was set to “Frame” and the frame size was 512 x 512. 
The scanning speed was set to 8. The pinhole for both channels was set to 1.35.  
Above parameters were used for all samples. However, it was not necessary to adjust 
the parameters each time: the “reuse” option in the ZEN 2009 software was used in 
order to reset all parameters automatically once they were configured for one 
picture.  
3.5.4.2. Imaging 
The microscopic slides prepared were applied on the microscope. Segregated cells 
were searched directly in the microscope. Once found, they were visualized in the 
ZEN 2009 software. The “Snap” option was chosen in order to have a first look at the 
staining. The “Range indicator” was used for each channel separately in order to 
adjust the offset and overexposure. For this, “Continuous scan” was started and the 
“Master gain” was increased (or decreased) just before red signals appear on the 
cells. The “Digital offset” was also adjusted in order to remove the blue background. 
Finally, both lasers were selected and the “Start experiment” option was chosen. The 
pictures were saved and used for further processing.  
3.5.4.3. Threshold setup 
In order to perform colocalization studies, first of all, single stainings were used to 
adjust the thresholds for each staining. For this, a single staining of the ERAD 
substrate (either a staining with RI lum, or with the HA.11, respectively) was opened 
in the ZEN 2009 software. The part “Colocalization” was selected, and in the case of 
HA.11 staining the vertical threshold was set up in a way that all dots (signals) 
remain limited to the 2nd scatter region. For RI lum staining, the signals were limited 
to the 1st scatter region. The same was done with single stainings of all antibodies.  
3.5.4.4. Raw colocalization data 
Once the thresholds were adjusted for all antibody combinations, double stainings 
were opened and the raw data located in the “Colocalization” part were copied to the 
clipboard, and further to a Microsoft Excel 2007 file. 
3.5.4.5. Statistical evaluation 
Statistical evaluation of the colocalization data was done with the statistics software 
SPSS 19.0 (IBM). First, variables were defined in the variable view folder for the 
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statistical evaluation of the influence of the inhibitors used on the ERAD substrate 
colocalization. The variables for each antibody combination (HA.11 vs. CALNEXIN, 
HA.11 vs. GIANTIN, RI lum vs. ERGIC53 and RI lum vs. CTR433) were defined in 
separate SPSS files as shown in table 9.  
In order to evaluate the ERAD substrate distribution in the different cellular 
compartments, SPSS files for each antibody and cell line combination were created 
with the variables shown in table 10. 
 
Name Type 
Column 
format 
Decimal 
number 
Value labels 
Missing 
values 
No. of 
columns 
Scale level 
Cells Number 8 0 
1=G3_RI332 
999 8 Nominal 
2=G3_RI332-6HA 
3=QC_RI332 
4=QC_RI332-6HA 
Condition Number 8 0 
1=Control 
999 8 Nominal 
2=CST 
3=KIF 
4=ZLLL 
CH3T2 Number 8 3 - 999 8 Scale 
CH3T2W Number 8 3 - 999 8 Scale 
Table 9. Variables used for statistical evaluation of the influence of the inhibitors on the ERAD substrate location.  
 
Name Type 
Column 
format 
Decimal 
number 
Value labels 
Missing 
values 
No. of 
columns 
Scale level 
Cells Number 8 0 
1=G3_RI332 
999 8 Nominal 
2=G3_RI332-6HA 
3=QC_RI332 
4=QC_RI332-6HA 
Combination 
of 
antibodies 
Number 8 0 
1=HA_GIANTIN 
999 8 Nominal 
2=HA_CALNEXIN 
3=RI_CTR433 
4=RI_ERGIC53 
CH3T2 / 
CH2T1 Number 8 3 - 999 8 Scale 
CH3T2W / 
CH2T1W Number 8 3 - 999 8 Scale 
Table 10. Variables used for statistical evaluation of ERAD substrate colocalization with different cellular compartments.  
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After defining all variables, raw data were copied from Microsoft Excel to the 
Dataview map in SSPS. In case of the 6HA tagged substrates, raw data from the CH3T2 
and CH3T2W were used. The CH3T2 colocalization coefficient is the number of red 
pixels (RI332-6HA signals) colocalized with green signals (Golgi apparatus or 
calnexin signals) with no respect on the signals intensity, whereas the CH3T2W 
colocalization coefficient takes the signal intensity into account. Raw data from the 
CH2T1 and CH2T1W channels were used for colocalization evaluation of the non-
tagged substrates. The CH2T1 colocalization coefficient is the number of green signals 
(RI and RI332 signals) colocalized with red signals (Golgi apparatus or ERGIC signals) 
with no respect on the signals intensity, whereas the CH2T1W colocalization 
coefficient taks the signal intensity into account.  Finally, a 2-sided t-test of 
independent samples was performed. The results of every t-test were collected in 
form of two tables which will be explained in the part 4. Results.  
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4. Results 
4.1. Half life determination of the ERAD substrates RI332 and RI332-6HA 
In the first part of this section (4.1.1. to 4.1.20; Figs. 15 to 34) a typical experiment 
(fluorogram and quantitation of densitometric scanning using a first order kinetics) 
for each cell line and condition is shown. Each experiment was performed at least in 
duplicate (mostly in triplicate), and the mean values were used for drawing the charts 
shown in figures 15 to 34.  For the determination of the degradation kinetics, the first 
chase time point was the 15 minutes time point, since for most of the experiments 
there was still an increase of the RI332 (and RI332-6HA, respectively) amount 
observed between 5’ and 15’ minutes, most likely due to a lag phase.  
In the second part (4.1.21; Figs. 35 to 36) an overview over all half life determinations 
by pulse chase experiments is given. This includes a statistical analysis for all sets of 
experiments. Table 11 gives an overview of the mean half life times, number of 
experiments and standard deviations for each experiment. 
4.1.1. Half life of RI-332 in the G3 cell line (clone 13) in absence of drugs 
Three pulse chase experiments were performed in order to determine the half life of 
RI332 in the G3 cell line (G3-RI332; clone 13). As seen in figure 15 (lower panel), the 
endogenous ribophorin I is stable during the whole chase period, while the relative 
amount of the ERAD substrate RI332 becomes less during chase time. The quantitation of 
the relative amounts of RI332 during the chase time determined by densitometric 
scanning is shown in upper panel of figure 15. The estimated mean half life of RI332 is 
47,19 ± 4,06 minutes. 
4.1.2. Half life of RI-332-6HA in the G3 cell line (clone 10) in absence of drugs 
Three pulse chase experiments were performed in order to determine the half life of 
RI332-6HA in the G3 cell line (G3-RI332-6HA; clone 10). The quantitation of the relative 
amounts of RI332-6HA during the chase time determined by densitometric scanning is 
shown in upper panel of figure 16. The tagged ERAD substrate RI332-6HA seems to be 
slightly more stable than the non-tagged variant (RI332 in G3-RI332; clone 13): 57,19 ± 
13,73 minutes  
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Figure 15. Above: relative amount of RI332 in G3 cells (clone 13) grown in the absence of inhibitors. Chase time points 15 
– 90 minutes. Below: fluorography of G3 RI-332 (clone 13) 
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Figure 16. Above: relative amount of RI332-6HA in G3 cells (clone 10) grown in the absence of inhibitors. Chase time 
points 15 – 90 minutes. Below: fluorography of G3 RI-332-6HA (clone 10) 
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Figure 17. Above: relative amount of RI332 in QC cells (clone GG) grown in the absence of inhibitors. Chase time points 15 
– 90 minutes. Below: fluorography of QC RI-332 (clone GG) 
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4.1.3. Half life of RI-332 in the QC cell line (clone GG) in absence of drugs 
Three pulse chase experiments were performed in order to determine the half life of 
RI332 in the QC cell line (QC-RI332; clone GG). From figure 17 it becomes obvious that the 
ERAD substrate RI332 is considerably less stable than in the G3 cell line. The mean half life 
determined in this cell line is 21,33 ± 4,64 minutes.   
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Figure 18. Above: relative amount of RI332-6HA in QC cells (clone 5) grown in the absence of inhibitors. Chase time points 
15 – 90 minutes. Below: fluorography of QC RI-332-6HA (clone 5) 
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4.1.4. Half life of RI-332-6HA in the QC cell line (clone 5) in absence of drugs 
Three pulse chase experiments were performed in order to determine the half life of 
RI332-6HA in the QC cell line (QC-RI332-6HA; clone 5). Similar to the non tagged form, 
RI332-6HA is significantly less stable than the tagged ERAD substrate in the G3 cell line. 
The mean half life determined is 17,84 ± 6,86 minutes.  
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Figure 19. Above: relative amount of RI332 in G3 cells (clone 13) grown in the presence of CST (inhibitor of glucosidases I 
& II). Chase time points 15 – 90 minutes. Below: fluorography of G3 RI-332 (clone 13) 
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4.1.5. Half life of RI-332 in the G3 cell line (clone 13) in presence of CST  
As shown in figure 19, the presence of CST slightly enhances the degradation of RI332 
in the G3 cell line. The inconsistent ribophorin I signal on the gel is most likely due to 
faulty pipetting. However, this is not distorting the results, because every signal for 
the ERAD substrate is normalized with the appropriate amount of ribophorin I. The 
half life time of RI332 in the G3 cell line, and in presence of CST, is 31,69 ± 3,46 min.   
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Figure 20. Above: relative amount of RI332-6HA in G3 cells (clone 10) grown in the presence of CST (inhibitor of 
glucosidases I & II). Chase time points 15 – 90 minutes. Below: fluorography of G3 RI-332-6HA (clone 10) 
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4.1.6. Half life of RI-332-6HA in the G3 cell line (clone 10) in presence of CST 
As shown in figure 20, CST enhances the degradation of RI332-6HA. This indicates that the 
two ERAD substrates (RI332 and RI332-6HA) seem to avoid the CNX cycle in the G3 cell 
lines. However, the degradation of RI332-6HA is negligible in contrast to the non tagged 
version in presence of CST (see figure 19 upper panel). The mean half life time of RI332-
6HA in the presence of CST is 49,48 ± 2,96 minutes.  
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Figure 21. Above: relative amount of RI332 in QC cells (clone GG) grown in the presence of CST (inhibitor of glucosidases I 
& II). Chase time points 15 – 90 minutes. Below: fluorography of QC RI-332 (clone GG) 
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4.1.7. Half life of RI-332 in the QC cell line (clone GG) in presence of CST 
In contrast to the G3 cell line, the degradation of RI332 surprisingly is not enhanced 
in the QC cells in presence of CST.  Actually, the RI332 is stabilized in the presence of 
CST. The half life time determined for the ERAD substrate in presence of CST is 68,15 
± 22,00 minutes.   
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Figure 22. Above: relative amount of RI332-6HA in QC cells (clone 5) grown in the presence of CST (inhibitor of 
glucosidases I & II). Chase time points 15 – 90 minutes. Below: fluorography of QC RI-332-6HA (clone 5) 
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4.1.8. Half life of RI-332-6HA in the QC cell line (clone 5) in presence of CST  
As for RI332, the tagged ERAD substrate is also stabilized in the presence of CST in 
the QC cells. The estimated mean half life of RI332-6HA is 47,97 ± 9,50 minutes.   
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Figure 23. Above: relative amount of RI332 in G3 cells (clone 13) grown in the presence of DMJ  (inhibitor of ER 
manosidases I & II). Chase time points 5 – 90 minutes. Below: fluorography of G3 RI-332 (clone 13) 
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4.1.9. Half life of RI-332 in the G3 cell line (clone 13) in presence of DMJ 
In order to estimate the half life of RI332 in G3 cells in presence of DMJ, three pulse 
chase experiments were performed. As seen in figure 23, DMJ dramatically influences 
the RI332 half life. The stabilized ERAD substrate has a mean half life time of 319,69 ± 
95,37 minutes.   
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Figure 24. Above: relative amount of RI332-6HA in G3 cells (clone 10) grown in the presence of DMJ  (inhibitor of ER 
manosidases I & II). Chase time points 5 – 90 minutes. Below: fluorography of G3 RI-332-6HA (clone 10) 
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4.1.10. Half life of RI-332-6HA in the G3 cell line (clone 10) in presence of DMJ  
The presence of DMJ stabilizes also the tagged ERAD substrate in G3 cells. The mean 
half life time of RI332-6HA is 535,96 ± 108,86 minutes.   
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Figure 25. Above: relative amount of RI332 in QC cells (clone GG) grown in the presence of DMJ  (inhibitor of ER 
manosidases I & II). Chase time points 5 – 90 minutes. Below: fluorography of QC RI-332 (clone GG) 
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4.1.11. Half life of RI-332 in the QC cell line (clone GG) in presence of DMJ 
In contrast to the G3 cells, DMJ seems to have no effect on the stability of RI332 in the 
QC cells. As seen in figure 25, the half life time of RI332 in presence of DMJ is hardly 
influenced: 28,54 ± 6,92 minutes. 
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Figure 26. Above: relative amount of RI332-6HA in QC cells (clone 5) grown in the presence of DMJ  (inhibitor of ER 
manosidases I & II). Chase time points 5 – 90 minutes. Below: fluorography of QC RI-332-6HA (clone 5) 
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4.1.12. Half life of RI-332-6HA in the QC cell line (clone 5) in presence of DMJ  
Unexpectedly, DMJ seems to influence the RI332-6HA stability in the QC cell line. The 
three pulse chase experiments indicate the consistency of the data. The mean half life 
time of the tagged ERAD substrate in presence of DMJ is 110,77 ± 3,80 minutes.    
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Figure 27. Above: relative amount of RI332 in G3 cells (clone 13) grown in the presence of KIF  (inhibitor of ER 
manosidases I & II). Chase time points 15 – 90 minutes. Below: fluorography of G3 RI-332 (clone 13) 
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4.1.13. Half life of RI-332 in the G3 cell line (clone 13) in presence of KIF  
As KIF is also an inhibitor of the ER mannosidases, the effect of KIF on the ERAD 
substrates is similar as in presence of DMJ. RI332 is stabilized by KIF in the G3 cell 
line. At time point 45’, less of ribophorin I and RI332 is present, which is most likely 
attributed to faulty pipetting. The estimated mean half life time of RI332 is 272,83 ± 
65,30 minutes.   
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Figure 28. Above: relative amount of RI332-6HA in G3 cells (clone 10) grown in the presence of KIF  (inhibitor of ER 
manosidases I & II). Chase time points 15 – 90 minutes. Below: fluorography of G3 RI-332-6HA (clone 10) 
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4.1.14. Half life of RI-332-6HA in the G3 cell line (clone 10) in presence of KIF  
As expected, RI332-6HA is stabilized by KIF in the G3 cell line. The mean half life time 
determined is 605,14 ± 67,82 minutes.   
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Figure 29. Above: relative amount of RI332 in QC cells (clone GG) grown in the presence of KIF (inhibitor of ER 
manosidases I & II). Chase time points 15 – 90 minutes. Below: fluorography of QC RI-332 (clone GG) 
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4.1.15. Half life of RI-332 in the QC cell line (clone GG) in presence of KIF 
Similar to DMJ, KIF seems to have hardly an influence on the stability of RI332 in the 
QC cell line. The estimated mean half life time of RI332 is 31,73 ± 0,43 minutes.    
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Figure 30. Above: relative amount of RI332-6HA in QC cells (clone 5) grown in the presence of KIF (inhibitor of ER 
manosidases I & II). Chase time points 15 – 90 minutes. Below: fluorography of QC RI-332-6HA (clone 5) 
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4.1.16. Half life of RI-332-6HA in the QC cell line (clone 5) in presence of KIF  
Due to inhibition of ER mannosidase I by KIF (and DMJ), RI332-6HA is stabilized even 
in the QC cells. This unexpected fact is indicated by consistent data derived from 
three pulse chase experiments. The half life time of RI332-6HA is 272,54 ± 56,13 
minutes.  
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Figure 31. Above: relative amount of RI332 in G3 cells (clone 13) grown in the presence of ZLLL (inhibitor of the 
proteasome). Chase time points 5 – 90 minutes. Below: fluorography of G3 RI-332 (clone 13) 
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4.1.17. Half life of RI-332 in the G3 cell line (clone 13) in presence of ZLLL  
Not surprisingly, the ERAD substrates are stabilized by the inhibition of the 
proteasome. In case of ZLLL, additional bands are seen in the later chase time points. 
This is due to the fact that only the degradation itself is inhibited, but not the 
trimming reactions. Therefore, the additional bands seen in figure 31 represent 
RI332 proteins with different sugar trees. The estimated mean half life time of RI332 
is: 266,97 ± 53,04 minutes.  
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Figure 32. Above: relative amount of RI332-6HA in G3 cells (clone 10) grown in the presence of ZLLL (inhibitor of the 
proteasome). Chase time points 5 – 90 minutes. Below: fluorography of G3 RI-332-6HA (clone 10) 
 
 
y = 102,98859e-0,00381x 
R² = 0,76274 
y = 114,79691e-0,01091x 
R² = 0,94352 
0 
20 
40 
60 
80 
100 
120 
0 15 30 45 60 75 90 
R
e
la
ti
ve
 a
m
o
u
n
t 
o
f 
R
I3
3
2
-6
H
A
 
Chase time [min] 
ZLLL Ohne Inhibitor No inhib tor 
4.1.18. Half life of RI-332-6HA in the G3 cell line (clone 10) in presence of ZLLL 
Analogous to the RI332 substrate, RI332-6HA is also stabilized by ZLLL in the G3 cell 
line. The different RI332 variants (with different sugar trees) are not that evident as 
in case of RI332, but they still can be seen in figure 32. The estimated half life time of 
RI332-6HA is 188,84 ± 25,87 minutes.   
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Figure 33. Above: relative amount of RI332 in QC cells (clone GG) grown in the presence of ZLLL (inhibitor of the 
proteasome). Chase time points 5 – 90 minutes. Below: fluorography of QC RI-332 (clone GG) 
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4.1.19. Half life of RI-332 in the QC cell line (clone GG) in presence of ZLLL  
The inhibition of the proteasome has the same effect in all cell lines, including the QC 
cells. A dramatic stabilization of the RI332 substrate in presence of ZLLL is obvious. 
The different RI332 trimming variants are especially present in the QC cell line (see 
figure below). The estimated half life time of the ERAD substrate is 110,17 ± 5,94 
minutes.   
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Figure 34. Above: relative amount of RI332-6HA in QC cells (clone 5) grown in the presence of ZLLL (inhibitor of the 
proteasome). Chase time points 5 – 90 minutes. Below: fluorography of QC RI-332-6HA (clone 5) 
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4.1.20. Half life of RI-332-6HA in the QC cell line (clone 5) in presence of ZLLL 
As expected, RI332-6HA is stabilized in the QC cell line by the presence of ZLLL. The 
estimated half life time of RI332-6HA is 194,37 ± 44,66 minutes.    
87 
 
 
47,19 31,69 
319,69 
272,83 266,97 
0 
100 
200 
300 
400 
500 
600 
700 
t1
/2
 [
m
in
] 
G3-RI332 (clone 13) 
w/i 
+CST 
+DMJ 
+KIF 
+ZLLL 
 
Figure 35. Above: half lives of RI332 in the absence and presence of inhibitors in G3 cells (clone 13). Below: half lives of 
RI332 – 6HA in the absence and presence of inhibitors in G3 cells (clone 10). 
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4.1.21. Overview of half lives of RI-332 and RI-332-6HA  
In figure 35, the half lives of RI332 and RI332-6HA in the G3 cells are graphically 
depicted. The stabilization of the substrates by DMJ, KIF and ZLLL is obvious. The 
effect observed is not that dramatic for the QC cells (figure 36). All half lives and 
standard deviations are shown in table 11.   
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Figure 36. Above: half lives of RI332 in the absence and presence of inhibitors in QC cells (clone GG). Below: half lives of 
RI332 – 6HA in the absence and presence of inhibitors in QC cells (clone 5). 
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4.2. Restoring of the wild type phenotype in the QC cell lines 
In this section (Figs. 37 to 40) a typical experiment (fluorogram and quantitation of 
densitometric scanning using a first order kinetics) for each cell line grown in the 
absence of inhibitors, but in presence or absence of galactose is shown.  
Pulse chase experiments of cells grown in the absence of galactose were only 
performed with five different chase time points (see figures 37 and 38). Pulse chase 
experiments of cells grown in presence of galactose were performed with seven time 
points. The estimated relative amounts of RI332 and RI332-6HA are graphically 
shown in figures 39 and 40. The relative amounts of the ERAD substrates are 
compared between cells grown in the presence of 6mM glucose (without galactose), 
5mM galactose and the standard RPMI 1640 growth medium (with glucose, without 
galactose).  
An overview of all half life times is shown in figure 41 (no standard deviations are 
shown due to the fact that these experiments were performed only once).  
Changes in morphology of QC cells grown in absence and presence of galactose are 
shown in figure 42. QC cells grown without galactose are more compact, whereas QC 
cells grown in the presence of galactose are more flat. The flat phenotype is 
characteristic to the wild type (G3) cells.   
Cell line ERAD substrate Inhibitor # of experiments t1/2 Standard deviation 
G3 RI332 RI332 None 3 47,19 4,06 
G3 RI332 RI332 CST 3 31,69 3,46 
G3 RI332 RI332 KIF 2 272,83 65,30 
G3 RI332 RI332 DMJ 3 319,69 95,37 
G3 RI332 RI332 ZLLL 3 266,97 53,04 
QC RI332 RI332 None 3 21,33 4,64 
QC RI332 RI332 CST 3 68,15 22,00 
QC RI332 RI332 KIF 2 31,73 0,43 
QC RI332 RI332 DMJ 3 28,54 6,92 
QC RI332 RI332 ZLLL 3 110,17 5,94 
G3 RI332-6HA RI332-6HA None 3 57,19 13,73 
G3 RI332-6HA RI332-6HA CST 3 49,48 2,96 
G3 RI332-6HA RI332-6HA KIF 2 605,14 67,82 
G3 RI332-6HA RI332-6HA DMJ 3 535,96 108,86 
G3 RI332-6HA RI332-6HA ZLLL 3 188,84 25,87 
QC RI332-6HA RI332-6HA None 3 17,84 6,86 
QC RI332-6HA RI332-6HA CST 3 47,97 9,50 
QC RI332-6HA RI332-6HA KIF 2 272,54 56,13 
QC RI332-6HA RI332-6HA DMJ 3 110,77 3,80 
QC RI332-6HA RI332-6HA ZLLL 3 194,37 44,66 
Table 11. Half live times of the ERAD substrates under different conditions in the four cell lines used 
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Figure 37. Fluorography of G3 RI332 and QC RI332 cells grown in the presence and absence of galactose 
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Figure 38. Fluorography of G3 RI332-6HA and QC RI332-6HA cells grown in the presence and absence of galactose 
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Figure 39. Above: relative amounts of RI332 in G3 RI-332 cells grown in i) the standard growth medium, ii) 6mM glucose growth 
medium and iii) 5mM galactose growth medium. Below: relative amounts of RI332-6HA in G3 RI332-6HA cells grown in i) the 
standard growth medium, ii) 6mM glucose growth medium and iii) 5mM galactose growth medium. 
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Figure 40. Above: relative amounts of RI332 in QC RI-332 cells grown in i) the standard growth medium, ii) 6mM glucose growth 
medium and iii) 5mM galactose growth medium. Below: relative amounts of RI332-6HA in QC RI332-6HA cells grown in i) the 
standard growth medium, ii) 6mM glucose growth medium and iii) 5mM galactose growth medium. 
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Figure 42. Restoring of the wt phenotype in QC RI332-6HA clone 5. Above: cells grown in absence of galactose (6mM glucose). 
Below: cells grown in presence of galactose (5mM) 
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Figure 41. Comparison of RI332 and RI332-6HA half lives in cell lines grown in different growth media.  
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4.3. ERAD substrate – calnexin association 
In this section (Figs. 43 to 50) a typical co-immuno precipitation experiment for each 
cell line is shown. Each fluorogram corresponds to one chase time point (details see 
images below). Each gel was exposed for one day and also for six days. The short 
exposure period was necessary to avoid a smear in the Cal (ns) lane. However, this 
short exposure was not sufficient to depict bands in the Cal/RI and RI/Cal lanes.   
 
Figure 43. Fluorography of co-immunoprecipitation. G3 RI332 clone 13. Chase time: 5’. Exposure time: 6 days (above) 
and 24 hours (below). RI lum and calnexin antibodies were used for stringent cell lysis (s) and non stringent cell lysis 
(ns). Co-immunoprecipitation was performed sequentially with calnexin – RI lum (Cal/RI) and RI lum – calnexin 
(RI/calnexin) antibodies, respectively.  
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For unknown reasons the ERAD substrates in the non stringent lane are at a slightly 
different height and/or show double bands in contrast to the stringent lane.   
 
 
Figure 44. Fluorography of co-immunoprecipitation. G3 RI332 clone 13. Chase time: 60’. Exposure time: 6 days (above) 
and 24 hours (below). RI lum and calnexin antibodies were used for stringent cell lysis (s) and non stringent cell lysis 
(ns). Co-immunoprecipitation was performed sequentially with calnexin – RI lum (Cal/RI) and RI lum – calnexin 
(RI/calnexin) antibodies, respectively. 
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Figure 45 Fluorography of co-immunoprecipitation. G3 RI332-6HA clone 10. Chase time: 5’. Exposure time: 6 days 
(above) and 24 hours (Below). RI lum and calnexin antibodies were used for stringent cell lysis (s) and non stringent cell 
lysis (ns). Co-immunoprecipitation was performed sequentially with calnexin – RI lum (Cal/RI) and RI lum – calnexin 
(RI/calnexin) antibodies, respectively. 
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Figure 46. Fluorography of co-immunoprecipitation. G3 RI332-6HA clone 10. Chase time: 60’. Exposure time: 6 days 
(above) and 24 hours (Below). RI lum and calnexin antibodies were used for stringent cell lysis (s) and non stringent cell 
lysis (ns). Co-immunoprecipitation was performed sequentially with calnexin – RI lum (Cal/RI) and RI lum – calnexin 
(RI/calnexin) antibodies, respectively. 
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Figure 47. Fluorography of co-immunoprecipitation. QC RI332 clone GG. Chase time: 5’. Exposure time: 6 days (above) 
and 24 hours (Below). RI lum and calnexin antibodies were used for stringent cell lysis (s) and non stringent cell lysis 
(ns). Co-immunoprecipitation was performed sequentially with calnexin – RI lum (Cal/RI) and RI lum – calnexin 
(RI/calnexin) antibodies, respectively. 
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Figure 48. Fluorography of co-immunoprecipitation. QC RI332 clone GG. Chase time: 60’. Exposure time: 6 days (above) 
and 24 hours (Below). RI lum and calnexin antibodies were used for stringent cell lysis (s) and non stringent cell lysis 
(ns). Co-immunoprecipitation was performed sequentially with calnexin – RI lum (Cal/RI) and RI lum – calnexin 
(RI/calnexin) antibodies, respectively. 
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Figure 49. Fluorography of co-immunoprecipitation. QC RI332-6HA clone 5. Chase time: 5’. Exposure time: 6 days 
(above) and 24 hours (Below). RI lum and calnexin antibodies were used for stringent cell lysis (s) and non stringent cell 
lysis (ns). Co-immunoprecipitation was performed sequentially with calnexin – RI lum (Cal/RI) and RI lum – calnexin 
(RI/calnexin) antibodies, respectively. 
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Figure 50. Fluorography of co-immunoprecipitation. QC RI332-6HA clone 5. Chase time: 60’. Exposure time: 6 days 
(above) and 24 hours (Below). RI lum and calnexin antibodies were used for stringent cell lysis (s) and non stringent cell 
lysis (ns). Co-immunoprecipitation was performed sequentially with calnexin – RI lum (Cal/RI) and RI lum – calnexin 
(RI/calnexin) antibodies, respectively. 
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In the figure below the relative interactions between the ERAD substrate and calnexin 
are shown. It is notable that the interaction is stronger in the G3 cell lines compared 
to the QC cell lines, especially at 5 minutes chase.    
Figure 51. Relative interaction between the ERAD substrates (RI332 and RI332-6HA) and calnexin. The signals for the 
ERAD substrates, after co-immunoprecipitation with calnexin – RI lum, were normalized with those from the endogenous 
ribophorin I from the stringent cell lysis. 
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4.4. Localization of the ERAD substrate 
In the first section (4.4.1. Fluorescence microscopy imaging), double stainings of the 
G3 and QC cells are presented. In the case of the non-tagged ERAD substrates (in G3 
RI332 and QC RI332 cells), RI332 was localized with the RI lum antibody and 
compared to two other compartments (ERGIC and Golgi apparatus). An analysis of co-
localization with the ER compartment was not possible, because no working 
monoclonal ER antibody was available. However, RI lum was also specific to the 
endogenous ribophorin I, although preferentially the tagged versions of the protein 
are stained (unpublished data).   
The HA tagged ERAD substrates (in G3 RI332-6HA and QC RI332-6HA cells) were 
specifically visualized with the HA.11 antibody. The RI332-6HA location was 
compared to two other compartments: ER and Golgi apparatus. No comparison to the 
ERGIC compartment was possible, because no working polyclonal antibody for the 
ERGIC was available. Figures 52 to 59 depict all double stainings in cells grown in 
absence and presence of inhibitors. It is obvious that all stainings worked properly 
with no (or negligible) background.  
In the second section (4.4.2. Statistical evaluation data of the colocalization assays) 
the appropriate estimated colocalization coefficients are presented. The results of the 
t-tests are given by SPSS in form of two tables. The first table gives information about 
the number of analyzed values (number of analyzed cells under given conditions), 
mean values of the colocalization coefficient and the standard deviations. In order to 
read the second table properly, the similarities of the variances should be checked. If 
the variances are similar (if the p value of the Levene test is greater than 0.05), the 
significance has to be read in the row “Variances are the same”. Otherwise, the 
significance has to be read in the row “Variances are not the same”. If the significance 
of the t-test is greater than 0.05, the null hypothesis will be retained. This means that 
no significant difference is present. If the significance of the t-test is smaller than 0.05, 
the alternative hypothesis will be applied (there is a significant difference between 
the two groups).  
For a better overview, the two standard SPSS output tables are shown only for one t-
test (tables 12 and 13). For all other t-tests, the data are filtered with respect to the 
variance of the Levene test. The filtered data are shown in tables 14 to 22.     
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4.4.1. Fluorescence microscopy imaging 
  
Figure 52. Double stainings of Golgi apparatus (GIANTIN polyclonal) and RI332-6HA (HA.11 monoclonal) in G3 cells 
(clone 10). Cells were grown in the absence of inhibitors, and in the presence of CST, KIF and ZLLL, respectively.  
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Figure 53. Double stainings of ER (CALNEXIN polyclonal) and RI332-6HA (HA.11 monoclonal) in G3 cells (clone 10). Cells 
were grown in the absence of inhibitors, and in the presence of CST, KIF and ZLLL, respectively.  
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Figure 54. Double stainings of Golgi apparatus (CTR433 monoclonal) and ribophorin I / RI332 (RI lum polyclonal) in G3 
cells (clone 13). Cells were grown in the absence of inhibitors, and in the presence of CST, KIF and ZLLL, respectively. 
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Figure 55. Double stainings of ERGIC (ERGIC53 monoclonal) and ribophorin I / RI332 (RI lum polyclonal) in G3 cells 
(clone 13). Cells were grown in the absence of inhibitors, and in the presence of CST, KIF and ZLLL, respectively.  
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Figure 56. Double stainings of Golgi apparatus (GIANTIN polyclonal) and RI332-6HA (HA.11 monoclonal) in QC cells 
(clone 5). Cells were grown in the absence of inhibitors, and in the presence of CST, KIF and ZLLL, respectively.  
110 
 
  
Figure 57. Double stainings of ER (CALNEXIN polyclonal) and RI332-6HA (HA.11 monoclonal) in QC cells (clone 5). Cells 
were grown in the absence of inhibitors, and in the presence of CST, KIF and ZLLL, respectively.  
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Figure 58. Double stainings of Golgi apparatus (CTR433 monoclonal) and ribophorin I / RI332 (RI lum polyclonal) in QC 
cells (clone GG). Cells were grown in the absence of inhibitors, and in the presence of CST, KIF and ZLLL, respectively.  
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Figure 59. Double stainings of ERGIC (ERGIC53 monoclonal) and ribophorin I / RI332 (RI lum polyclonal) in QC cells 
(clone GG). Cells were grown in the absence of inhibitors, and in the presence of CST, KIF and ZLLL, respectively.  
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4.4.2. Statistical evaluation data of the colocalization assays 
In the first part of this section (tables 12 to 17), the influence of inhibitors on the 
ERAD substrate localization will be analyzed. For the influence of CST in G3-RI332-
6HA cells (clone 10), the original tables generated by SPSS are shown (tables 12 and 
13). The original tables are in German language. Results from other t-tests for the 
inhibitor influence on the ERAD substrate localization are shown in tables 14 to 17. In 
the second part, t-tests for the co-localizations of the ERAD substrates with other 
compartments are shown in tables 18 to 22. 
 The first table generated by the SPSS software (table 12) gives information about the 
conditions (which inhibitor was used), number of samples (the average number of 
samples is between 10-15, but in some exceptions less samples were used for the 
statistical evaluation), mean value of the appropriate localization coefficients, the 
standard deviation and the standard error of the mean value. For each statistical 
evaluation, two different co-localization coefficients were used: i) co-localization 
coefficients with no respect to signal intensity (counts only how many signals of one 
channel overlap with signals of the other channel) and ii) co-localization coefficients 
with respect to signal intensities (weighted co-localization coefficients). The weighted 
coefficients are labeled with a “W” (in the example shown in tables 12 and 13, the 
coefficients with no respect to the intensities are called “CH3T2”, and the weighted 
coefficients are named “CH3T2W”).  
 
 
 
 
 
 
 
 
 
 
 
 
Kanal Condition N Mittelwert Standardabweichung 
Standardfehler des 
Mittelwertes 
CH3T2 
Control 11 ,06082 ,009293 ,002802 
CST 12 ,06233 ,016827 ,004858 
CH3T2W 
Control 11 ,06936 ,016812 ,005069 
CST 12 ,04558 ,009150 ,002641 
Table 12. Group statistics 
 
Levene-Test  T-Test für die Mittelwertgleichheit 
F Sig. 
 
T df Sig.  Mittlere 
Differenz 
Standard-
Fehler der 
Differenz 
95% Konfidenzintervall 
der Differenz 
Untere Obere 
CH3T2 
Varianzen sind gleich 4,610 ,044 -,264 21 ,795 -,001515 ,005745 -,013463 ,010433 
Varianzen sind nicht gleich 
  
-,270 17,417 ,790 -,001515 ,005608 -,013325 ,010295 
CH3T2W 
Varianzen sind gleich 5,164 ,034 4,265 21 ,000 ,023780 ,005576 ,012184 ,035377 
Varianzen sind nicht gleich 
  
4,160 15,152 ,001 ,023780 ,005716 ,011608 ,035953 
Table 13. Example of a t-test of independent samples 
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In the second table generated by SPSS (table 13), the results of the Levene test and 
the t-test of independent samples are shown. First of all, the significance of the 
Levene test has to be checked. If the significance is >0.05, then the t-test has to be 
read off in the column “Varianzen sind gleich” (variances are the same). If the 
significance of the Levene test is <0.05, the t-test has to be read off in the column 
“Varianzen sind nicht gleich” (variances are different). In the example shown in table 
13, the variances (for the weighted and the non-weighted coefficients) of the Levene 
tests are less than 0.05. Therefore, the t-test will be read off in the column “Varianzen 
sind gleich”).  
The relevant information of the t-test is the significance (t-test significance). If the 
significance is >0.05, then no significant differences are present for the two groups. If 
the significance is <0.05, significant differences between the two groups are present.  
All t-tests for the G3-RI332 and QC-RI332 cells (grown under different conditions) 
with the antibody combination RI lum vs. CTR433 are shown in table 14. The t-test 
for the same cells and conditions, but with the RI lum vs. ERGIC53 antibody 
combination is shown in table 15.  
 
 
 
 
  
  
Cell line and 
antibodies 
Channel Condition N 
Mean 
value 
Standard 
deviation 
Levene 
test (sig.) 
t-test 
(sig.) 
Interpretation 
G3-RI332 
(clone 13) 
 
RI lum / 
CTR433 
CH2T1 
Control 10 0,0337 0,005282 
0,136 0,010 
There is a significant 
difference CST 6 0,0210 0,009274 
CH2T1W 
Control 10 0,0417 0,005559 
0,049 0,013 
There is a significant 
difference CST 6 0,0230 0,012522 
CH2T1 
Control 10 0,0337 0,005282 
0,680 0,253 
There is no significant 
difference KIF 7 0,0300 0,006245 
CH2T1W 
Control 10 0,0417 0,005559 
0,889 0,000 
There is a significant 
difference KIF 7 0,0271 0,005699 
CH2T1 
Control 10 0,0337 0,005282 
0,068 0,979 
There is no significant 
difference ZLLL 7 0,0336 0,009127 
CH2T1W 
Control 10 0,0417 0,005559 
0,146 0,608 
There is no significant 
difference ZLLL 7 0,0392 0,010849 
QC-RI332 
(clone GG) 
 
RI lum / 
CTR433 
CH2T1 
Control 10 0,0448 0,006517 
0,773 0,000 
There is a significant 
difference CST 10 0,0123 0,005832 
CH2T1W 
Control 10 0,0604 0,10245 
0,804 0,000 
There is a significant 
difference CST 10 0,0156 0,10080 
CH2T1 
Control 10 0,0448 0,006517 
0,109 0,000 
There is a significant 
difference KIF 8 0,0235 0,004567 
CH2T1W 
Control 10 0,0604 0,010245 
0,046 0,000 
There is a significant 
difference KIF 8 0,0287 0,007146 
CH2T1 
Control 10 0,0448 0,006517 
0,003 0,000 
There is a significant 
difference ZLLL 6 0,0288 0,001941 
CH2T1W 
Control 10 0,0604 0,010245 
0,000 0,002 
There is a significant 
difference ZLLL 6 0,0415 0,001871 
Table 14. T-tests for the G3-RI332 (clone 13) and QC-RI332 (clone GG) cells, grown in the presence and absence of 
inhibitors; RI lum vs. CTR433 antibodies. 
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  Cell line and 
antibodies 
Channel Condition N 
Mean 
value 
Standard 
deviation 
Levene 
test (sig.) 
t-test 
(sig.) 
Interpretation 
G3-RI332 
(clone 13) 
 
RI lum / 
ERGIC53 
CH2T1 
Control 10 0,0415 0,004860 
0,009 0,477 
There is no significant 
difference CST 9 0,0445 0,010853 
CH2T1W 
Control 10 0,0528 0,004059 
0,004 0,913 
There is no significant 
difference CST 9 0,0522 0,016262 
CH2T1 
Control 10 0,0415 0,004860 
0,007 0,600 
There is no significant 
difference KIF 7 0,0457 0,019345 
CH2T1W 
Control 10 0,0528 0,004059 
0,002 0,877 
There is no significant 
difference KIF 7 0,0544 0,025422 
CH2T1 
Control 10 0,0415 0,004860 
0,000 0,898 
There is no significant 
difference ZLLL 7 0,0430 0,028671 
CH2T1W 
Control 10 0,0528 0,004059 
0,000 0,888 
There is no significant 
difference ZLLL 7 0,0556 0,040759 
QC-RI332 
(clone GG) 
 
RI lum / 
ERGIC53 
CH2T1 
Control 15 0,0682 0,013078 
0,626 0,000 
There is a significant 
difference CST 12 0,0377 0,010954 
CH2T1W 
Control 15 0,0895 0,019114 
0,075 0,000 
There is a significant 
difference CST 12 0,0377 0,012174 
CH2T1 
Control 15 0,0682 0,013078 
0,338 0,005 
There is a significant 
difference KIF 14 0,0497 0,018684 
CH2T1W 
Control 15 0,0895 0,018114 
0,138 0,016 
There is a significant 
difference KIF 14 0,0665 0,029070 
CH2T1 
Control 15 0,0682 0,013078 
0,001 0,855 
There is no significant 
difference ZLLL 7 0,0712 0,042145 
CH2T1W 
Control 15 0,0895 0,018114 
0,012 0,976 
There is no significant 
difference ZLLL 7 0,0901 0,049627 
Table 15. T-tests for the G3-RI332 (clone 13) and QC-RI332 (clone GG) cells, grown in the presence and absence of 
inhibitors; RI lum vs. ERGIC53 antibodies.   
 
Cell line and 
antibodies 
Channel Condition N 
Mean 
value 
Standard 
deviation 
Levene 
test (sig.) 
t-test 
(sig.) 
Interpretation 
G3-RI332-6HA 
(clone 10) 
 
HA.11 / 
CALNEXIN 
CH3T2 
Control 15 0,9952 0,004026 
0,003 0,002 
There is a significant 
difference CST 11 0,9991 0,001250 
CH3T2W 
Control 15 0,9983 0,001633 
0,002 0,006 
There is a significant 
difference CST 11 0,9997 0,000467 
CH3T2 
Control 15 0,9952 0,004026 
0,261 0,112 
There is no significant 
difference KIF 12 0,9975 0,003059 
CH3T2W 
Control 15 0,9983 0,001633 
1,000 0,802 
There is no significant 
difference KIF 12 0,9985 0,001784 
CH3T2 
Control 15 0,9952 0,004026 
0,000 0,004 
There is a significant 
difference ZLLL 14 0,9580 0,040053 
CH3T2W 
Control 15 0,9983 0,001633 
0,000 0,003 
There is a significant 
difference ZLLL 14 0,9769 0,022179 
QC-RI332-6HA 
(clone 5) 
 
HA.11 / 
CALNEXIN 
CH3T2 
Control 15 0,9920 0,015177 
0,012 0,100 
There is no significant 
difference CST 11 0,9990 0,001414 
CH3T2W 
Control 15 0,9958 0,005809 
0,007 0,072 
There is no significant 
difference CST 11 0,9997 0,000467 
CH3T2 
Control 15 0,9920 0,015177 
0,026 0,133 
There is no significant 
difference KIF 10 0,9984 0,002413 
CH3T2W 
Control 15 0,9968 0,005809 
0,017 0,097 
There is no significant 
difference KIF 10 0,9995 0,000850 
CH3T2 
Control 15 0,9920 0,015177 
0,014 0,069 
There is no significant 
difference ZLLL 9 0,9997 0,000441 
CH3T2W 
Control 15 0,9958 0,005809 
0,007 0,051 
There is no significant 
difference ZLLL 9 1,0000 0,000000 
Table 16. T-tests for the G3-RI332-6HA (clone 10) and QC-RI332-6HA (clone 5) cells, grown in the presence and 
absence of inhibitors; HA.11 vs. CALNEXIN antibodies.   
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Beside the statistical evaluation of the influence of inhibitors on the co-colocalization 
of RI332 (and RI332-6HA, respectively) with specific cellular compartments, also the 
co-localization coefficients of different antibody combinations were compared among 
themselves. For this purpose, only co-localization coefficients of cells grown in the 
absence of inhibitors were used (only one condition). The t-test results for all cell 
lines are shown in tables 18 to 22. The comparisons of the antibody combinations are 
shown below. 
 HA.11/GIANTIN vs. HA.11/CALNEXIN 
 HA.11/GIANTIN vs RI lum/CTR433 
 HA.11/GIANTIN vs. RI lum/ERGIC53 
 HA.11/CALNEXIN vs. RI lum/CTR433 
 HA.11/CALNEXIN vs RI lum/ERGIC53 
  
Cell line and 
antibodies 
Channel Condition N 
Mean 
value 
Standard 
deviation 
Levene 
test (sig.) 
t-test 
(sig.) 
Interpretation 
G3-RI332-6HA 
(clone 10) 
 
HA.11 / 
GIANTIN 
CH3T2 
Control 11 0,0608 0,009293 
0,044 0,790 
There is no significant 
difference CST 12 0,0623 0,016827 
CH3T2W 
Control 11 0,0693 0,016812 
0,034 0,001 
There is a significant 
difference CST 12 0,0455 0,009150 
CH3T2 
Control 11 0,0608 0,009293 
0,110 0,000 
There is a significant 
difference KIF 9 0,0362 0,005094 
CH3T2W 
Control 11 0,0693 0,06936 
0,025 0,000 
There is a significant 
difference KIF 9 0,0383 0,03833 
CH3T2 
Control 11 0,0608 0,009293 
0,002 0,004 
There is a significant 
difference ZLLL 11 0,0933 0,029090 
CH3T2W 
Control 11 0,0693 0,016812 
0,029 0,030 
There is a significant 
difference ZLLL 11 0,0970 0,034205 
QC-RI332-6HA 
(clone 5) 
 
HA.11 / 
GIANTIN 
CH3T2 
Control 16 0,0925 0,018323 
0,574 0,023 
There is a significant 
difference CST 8 0,0716 0,022379 
CH3T2W 
Control 16 0,0990 0,022238 
0,372 0,000 
There is a significant 
difference CST 8 0,0615 0,016767 
CH3T2 
Control 16 0,0925 0,018323 
0,107 0,123 
There is no significant 
difference KIF 10 0,1076 0,030034 
CH3T2W 
Control 16 0,0990 0,022238 
0,021 0,864 
There is no significant 
difference KIF 10 0,0963 0,039463 
CH3T2 
Control 16 0,0925 0,018323 
0,094 0,005 
There is a significant 
difference ZLLL 12 0,1215 0,031306 
CH3T2W 
Control 16 0,0990 0,022238 
0,002 0,001 
There is a significant 
difference ZLLL 12 0,6066 0,062571 
Table 17. T-tests for the G3-RI332-6HA (clone 10) and QC-RI332-6HA (clone 5) cells, grown in the presence and 
absence of inhibitors; HA.11 vs. GIANTIN antibodies.  
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HA.11/GIANTIN vs. HA.11/CALNEXIN 
Cell line 
combinations 
Channel Antibodies N 
Mean 
value 
Standard 
deviation 
Levene 
test 
(sig.) 
t-test 
(sig.) 
Interpretation 
G3-RI332-6HA 
vs. 
G3-RI332-6HA 
CH2T1 
(CH3T2) 
HA_GIANTIN 11 0,0608 0,009293 
0,028 0,000 
There is a significant 
difference HA_CALNEXIN 15 0,9952 0,004026 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 11 0,0693 0,016812 
0,000 0,000 
There is a significant 
difference HA_CALNEXIN 15 0,9983 0,001633 
G3-RI332-6HA 
vs. 
QC-RI332-6HA 
CH2T1 
(CH3T2) 
HA_GIANTIN 13 0,0990 0,012800 
0,997 0,000 
There is a significant 
difference HA_CALNEXIN 15 0,9920 0,015177 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 13 0,1062 0,017331 
0,001 0,000 
There is a significant 
difference HA_CALNEXIN 15 0,9968 0,005809 
Table 18. Comparison of HA.11/GIANTIN and HA.11/CALNEXIN co-localizations. 
 
HA.11/GIANTIN vs. RI lum/CTR433 
Cell line 
combinations 
Channel Antibodies N 
Mean 
value 
Standard 
deviation 
Levene 
test 
(sig.) 
t-test 
(sig.) 
Interpretation 
G3-RI332-6HA 
vs. 
G3-RI332 
CH2T1 
(CH3T2) 
HA_GIANTIN 12 0,0570 0,007032 
0,028 0,021 
There is a significant 
difference RI_CTR433 8 0,0453 0,010836 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 12 0,0643 0,013432 
0,452 0,056 
There is no significant 
difference RI_CTR433 8 0,0523 0,010070 
G3-RI332-6HA 
vs. 
QC-RI332 
CH2T1 
(CH3T2) 
HA_GIANTIN 12 0,0616 0,013776 
0,566 0,063 
There is no significant 
difference RI_CTR433 7 0,0446 0,009292 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 12 0,0709 0,021157 
0,321 0,482 
There is no significant 
difference RI_CTR433 7 0,0616 0,012097 
QC-RI332-6HA 
vs. 
G3-RI332 
CH2T1 
(CH3T2) 
HA_GIANTIN 16 0,0925 0,018323 
0,030 0,000 
There is a significant 
difference RI_CTR433 7 0,0337 0,005282 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 16 0,0990 0,022238 
0,015 0,000 
There is a significant 
difference RI_CTR433 7 0,0417 0,005559 
QC-RI332-6HA 
vs. 
QC-RI332 
CH2T1 
(CH3T2) 
HA_GIANTIN 16 0,0925 0,018323 
0,067 0,000 
There is a significant 
difference RI_CTR433 7 0,0448 0,006517 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 16 0,0990 0,022238 
0,112 0,013 
There is a significant 
difference RI_CTR433 7 0,0604 0,010245 
Table 19. Comparison of HA.11/GIANTIN and RI lum/CTR433 co-localizations. 
 
HA.11/GIANTIN vs. RI lum/ERGIC53 
Cell line 
combinations 
Channel Antibodies N 
Mean 
value 
Standard 
deviation 
Levene 
test 
(sig.) 
t-test 
(sig.) 
Interpretation 
G3-RI332-6HA 
vs. 
G3-RI332 
CH2T1 
(CH3T2) 
HA_GIANTIN 11 0,0608 0,009293 
0,183 0,000 
There is a significant 
difference RI_ERGIC53 7 0,0415 0,004860 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 11 0,0693 0,016812 
0,008 0,009 
There is a significant 
difference RI_ ERGIC53 7 0,0528 0,004059 
G3-RI332-6HA 
vs. 
QC-RI332 
CH2T1 
(CH3T2) 
HA_GIANTIN 11 0,0608 0,009293 
0,339 0,158 
There is no significant 
difference RI_ ERGIC53 14 0,0677 0,013469 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 11 0,0693 0,016812 
0,516 0,011 
There is a significant 
difference RI_ ERGIC53 14 0,0892 0,018772 
QC-RI332-6HA 
vs. 
G3-RI332 
CH2T1 
(CH3T2) 
HA_GIANTIN 16 0,0925 0,018323 
0,029 0,000 
There is a significant 
difference RI_ ERGIC53 7 0,0415 0,004860 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 16 0,0990 0,022238 
0,009 0,000 
There is a significant 
difference RI_ ERGIC53 7 0,0528 0,004059 
QC-RI332-6HA 
vs. 
QC-RI332 
CH2T1 
(CH3T2) 
HA_GIANTIN 16 0,0925 0,018323 
0,236 0,000 
There is a significant 
difference RI_ ERGIC53 15 0,0682 0,013078 
CH2T1w 
(CH3T2w) 
HA_GIANTIN 16 0,0990 0,022238 
0,568 0,206 
There is no significant 
difference RI_ ERGIC53 15 0,0895 0,018114 
Table 20. Comparison of HA.11/GIANTIN and RI lum/ERGIC53 co-localizations. 
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HA.11/CALNEXIN vs. RI lum/CTR433 
Cell line 
combinations 
Channel Antibodies N 
Mean 
value 
Standard 
deviation 
Levene 
test 
(sig.) 
t-test 
(sig.) 
Interpretation 
G3-RI332-6HA 
vs. 
G3-RI332 
CH2T1 
(CH3T2) 
HA_CALNEXIN 15 0,9952 0,004026 
0,693 0,000 
There is a significant 
difference RI_ CTR433 7 0,0337 0,005282 
CH2T1w 
(CH3T2w) 
HA_ CALNEXIN 15 0,9983 0,001633 
0,005 0,000 
There is a significant 
difference RI_ CTR433 7 0,0417 0,005559 
G3-RI332-6HA 
vs. 
QC-RI332 
CH2T1 
(CH3T2) 
HA_ CALNEXIN 15 0,9952 0,004026 
0,036 0,000 
There is a significant 
difference RI_ CTR433 7 0,0448 0,006517 
CH2T1w 
(CH3T2w) 
HA_ CALNEXIN 15 0,9983 0,001633 
0,000 0,000 
There is a significant 
difference RI_ CTR433 7 0,0604 0,010245 
QC-RI332-6HA 
vs. 
G3-RI332 
CH2T1 
(CH3T2) 
HA_ CALNEXIN 15 0,9920 0,015177 
0,149 0,000 
There is a significant 
difference RI_ CTR433 7 0,0337 0,005282 
CH2T1w 
(CH3T2w) 
HA_ CALNEXIN 15 0,9968 0,005809 
0,939 0,000 
There is a significant 
difference RI_ CTR433 7 0,0417 0,005559 
QC-RI332-6HA 
vs. 
QC-RI332 
CH2T1 
(CH3T2) 
HA_ CALNEXIN 15 0,9920 0,015177 
0,292 0,000 
There is a significant 
difference RI_ CTR433 7 0,0448 0,006517 
CH2T1w 
(CH3T2w) 
HA_ CALNEXIN 15 0,9968 0,99680 
0,005 0,000 
There is a significant 
difference RI_ CTR433 7 0,0604 0,06043 
Table 21. Comparison of HA.11/CALNEXIN and RI lum/CTR433 co-localizations. 
 
HA.11/CALNEXIN vs. RI lum/ERGIC53 
Cell line 
combinations 
Channel Antibodies N 
Mean 
value 
Standard 
deviation 
Levene 
test 
(sig.) 
t-test 
(sig.) 
Interpretation 
G3-RI332-6HA 
vs. 
G3-RI332 
CH2T1 
(CH3T2) 
HA_CALNEXIN 15 0,9952 0,004026 
0,630 0,000 
There is a significant 
difference RI_ ERGIC53 7 0,0415 0,004860 
CH2T1w 
(CH3T2w) 
HA_ CALNEXIN 15 0,9983 0,001633 
0,005 0,000 
There is a significant 
difference RI_ ERGIC53 7 0,0528 0,004059 
G3-RI332-6HA 
vs. 
QC-RI332 
CH2T1 
(CH3T2) 
HA_ CALNEXIN 15 0,9952 0,004026 
0,008 0,000 
There is a significant 
difference RI_ ERGIC53 15 0,0682 0,013078 
CH2T1w 
(CH3T2w) 
HA_ CALNEXIN 15 0,9983 0,001633 
0,000 0,000 
There is a significant 
difference RI_ ERGIC53 15 0,0895 0,018114 
QC-RI332-6HA 
vs. 
G3-RI332 
CH2T1 
(CH3T2) 
HA_ CALNEXIN 15 0,9920 0,015177 
0,148 0,000 
There is a significant 
difference RI_ ERGIC53 7 0,0415 0,004860 
CH2T1w 
(CH3T2w) 
HA_ CALNEXIN 15 0,9968 0,005809 
0,645 0,000 
There is a significant 
difference RI_ ERGIC53 7 0,0528 0,004059 
QC-RI332-6HA 
vs. 
QC-RI332 
CH2T1 
(CH3T2) 
HA_ CALNEXIN 15 0,9920 0,015177 
0,886 0,000 
There is a significant 
difference RI ERGIC53 15 0,0682 0,013078 
CH2T1w 
(CH3T2w) 
HA_ CALNEXIN 15 0,9968 0,005809 
0,000 0,000 
There is a significant 
difference RI_ ERGIC53 15 0,0895 0,018144 
Table 22. Comparison of HA.11/CALNEXIN and RI lum/ERGIC53 co-localizations. 
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5. Discussion 
The majority of secretory proteins are N-linked glycoproteins. The complex N-linked 
oligosaccharide (Glc3Man9GlcNAc2) is extensively trimmed and modified in the ER 
and further compartments of the secretory pathway. The trimming is necessary in 
order to promote quality control of folding, maturation and assembling of the 
proteins (Lederkremer, 2009).  
UDP-glucose (UDP-glc) plays a crucial role in the assembly of the N-linked glycan and 
in the quality control of glycoproteins. UDP-glc is a precursor of Dol-P-glucose which 
is a glucose donor for the N-linked glycan (Burda, et al., 1999). During the CNX cycle, 
UDP-glc is used by the central enzyme UDP-Glc:glycoprotein glucosyltransferase (GT) 
in order to reglucosylate unfolded and misfolded proteins (see 1.5.2. CNX cycle).  
During the first part of this diploma thesis, the degradation efficiency of two model 
proteins (ERAD substrates: RI332 and RI332-6HA) was investigated by pulse chase 
experiments. These proteins were expressed in two different cell lines, which had 
been originally generated from a Chinese hamster lung fibroblast cell line with a 
dective UDP-glucose pyrophosphorylase (Flores-Diaz, et al., 1997): i) G3 and ii) QC. 
The G3 cell line has a restored wild type phenotype, due to a stable transfection with 
a vector carrying the cDNA of the bovine UDP-glucose pyrophosphorylase gene. The 
QC cell line was transfected with an empty vector, resulting in the mutant phenotype. 
As a consequence, the QC cells have low levels of UDP-glc and thus glucosylation 
reactions are affected. Because of low levels of UDP-glc, the N-linked glycans are 
missing the three glucose molecules (S.E. Moore, unpublished observations). 
Consequently, the degradation of the ERAD substrates would be expected to be faster 
in the QC cells compared to G3 cells, because glycoproteins with N-linked glycans 
would be expected not to enter the CNX cycle which usually causes a temporary 
retention of glycoproteins in the ER (see 1.5.2. CNX cycle). 
In the second part of this diploma thesis, the interaction between the ERAD 
substrates and CNX was analyzed by sequential immunoprecipitation. It has already 
been described that terminally misfolded glycoproteins are guided by the CNX cycle 
to the ERAD pathway (Benyair, et al., 2011). 
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Finally, the last part of the diploma thesis was focused on the intracellular localization 
of the ERAD substrates. It was analyzed by indirect immunofluorescence and confocal 
laser scanning microscopy whether interfering with the ER quality control by using 
drugs that inhibit initial processing of the N-linked glycan or proteasomal 
degradation affects the localization of the two ERAD model substrates (RI332 and 
RI332-6HA). Furthermore, using a colocalization module of the microscope software 
(see 4.5.2. Visualization), the colocalization coefficients of the ERAD substrates and 
designated cellular compartments were compared among themselves.  
5.1. Half life determination of the ERAD substrates RI332 and RI332-6HA 
Not surprisingly, the half lives of the two ERAD substrates RI332 and RI332-6HA are 
considerably shorter in the mutant cell lines QC-RI332 (RI332 t1/2: 21,33±4,64 
minutes) and QC-RI332-6HA (RI-332-6HA t1/2: 18,84±6,86 minutes) rather than in 
the wild type cell lines G3-RI332 (RI332 t1/2: 47,19±4,06 minutes) and G3-RI332-6HA 
(RI332-6HA t1/2: 57,19±13,73 minutes) (see figures 15 to 18). Due to the mutation in 
UDP-glucose pyrophosphorylase, N-glucosylation is disturbed in QC cells. As a 
consequence, the proteins are not recognized by the players of the CNX cycle, which 
requires that glycoproteins are monoglucosylated (Williams, 2006). Therefore, RI-
332 and RI-332-6HA appear to avoid the CNX cycle which at the end causes a faster 
retrotranslocaion to the cytosol, followed by proteasomal degradation. 
The ERAD substrates in the G3 cell lines are properly glucosylated; they have first to 
be processed by glucosidases I & II in order to enter the CNX cycle (D'Alessio, et al., 
2010; Pearse & Hebert, 2010). Once the proteins have entered the CNX cycle, they 
have to go through several cycles before they can be released. The release is initiated 
by the delayed action of ER mannosidase I (Bagola, et al., 2011; Benyair, et al., 2011). 
In further experiments, inhibitors were used in order to interfere with the ER quality 
control. The ER quality control was disturbed by the inhibition of i) glucosidase I by 
CST, ii) ER mannosidase I by DMJ or KIF, and iii) the proteasome by ZLLL.  
5.2. Effect of inhibitors on the ERAD substrate degradation 
The first oligosaccharide trimming of properly N-glycosylated proteins occurs in the 
ER by glucosidases I & II. These two enzymes remove the two outermost glucose 
molecules of the oligosaccharide. By inhibiting their action, glycoproteins remain fully 
glucosylated. They are not recognized by CNX and CRT, which recognize only 
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monoglucosylated glycoproteins (Williams, 2006). According to expectations, these 
proteins should be retrotranslocated faster than in the normal situation when the 
glucose residues are cleaved off. 
On the other hand, the inhibition of glucosidase I should not affect the destiny of non-
glucosylated secretory proteins as they occur in QC cells. These proteins should not 
enter the CNX cycles at all. 
As expected, the degradation of RI332 and RI332-6HA in the G3 cells becomes slightly 
faster in the presence of CST (RI332 half life decreases for approx. 33% and the 
RI332-6HA half life decreases for approx. 13%). This is perhaps an indication that the 
CNX cycle is at least partially avoided, because of the pre-incubation with CST that 
causes the inhibition of glucosidase I. However, the faster degradation is more 
apparent for the non-tagged ERAD substrate (RI332) (see figures 19 and 20). 
Surprisingly, CST caused changes in the stability of the ERAD substrates in the QC 
cells. As seen in figures 21 and 22, RI332 and RI332-6HA are stabilized by the 
inhibition of glucosidase I (the half life of RI332 increased for approximately 220% 
and the half life of RI332-6HA increased for approximately 169%). This could be 
explained by a re-glucosylation of the ERAD substrates by UDP-glucose glycoprotein 
glucosyltransferase, and a prolonged interaction with CNX, which appears unlikely, 
however. An alternative explanation would be that the ERAD substrates enter an 
unknown degradation pathway in the QC cells.   
Two different inhibitors of ER mannosidase I were used: i) KIF, a non-competitive 
inhibitor and ii) DMJ, a competitive inhibitor. By inhibiting ER mannosidases in the 
G3 cells, misfolded glycoproteins should retain trapped in the CNX cycle. In other 
words, the misfolded protein should be stabilized and retained in the ER. In QC cells, 
the inhibition of ER mannosidases should not affect the degradation of the ERAD 
substrates, since the ERAD substrates should not enter the CNX cycle. 
As shown in figures 23, 24, 27 and 28, treatment of cells with both ER mannosidase 
inhibitors indeed increases the half lives of the ERAD substrates in G3 cells (DMJ 
increases the half life of RI332 for approx. 577% and of RI332-6HA for approx. 
830%). The dramatic stabilisation is better shown in figure 35. In QC cells, the half life 
of the non-tagged ERAD substrate is only negligibly changed in the presence of both 
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inhibitors (DMJ increases the half life of RI332 for approximately 34%) (see figures 
25 and 29). This finding confirms the assumption that the misfolded glycoproteins in 
QC cells partially avoid the CNX cycle. However, unexpectedly the tagged ERAD 
substrate (RI332-6HA) in the QC cells is stabilized by the ER mannosidases inhibitors 
(DMJ increases the half life of RI332-6HA for approx. 521%) (see figures 26 and 30). 
This suggests that the protein does enter the CNX cycle. It is possible that the 6HA tag 
changes the properties of the glycoprotein in an unknown way. Alternatively, ER 
mannosidase I or another ER mannosidase that is inhibited by KIF and DMJ may be 
involved in the degradation of the HA-tagged ERAD substrate in QC cells.  
Finally, interfering with the ER quality control was also performed on the 
degradation level of ERAD itself. The proteasome was inhibited by ZLLL. The 
inhibition of the proteasome should stabilize all misfolded glycoproteins, 
independently of the glycosylation status and the cell line. As seen in figures 31 to 34, 
ZLLL treatment of cells indeed causes dramatic stabilization of both ERAD substrates 
in all cases (ZLLL increases the half life of RI332 in G3 cells for approx. 460% and in 
QC cells for approx. 415%. Similarly, ZLLL increases the half life of RI332-6HA in G3 
cells for approx. 230% and in QC cells for approx. 990%).  
Another observation in the fluorograms of cells grown in presence of ZLLL is that 
additional bands can be seen beneath the RI332 and RI332-6HA bands, respectively. 
Those bands represent accumulated glycoproteins with different trimming levels (see 
also Kitzmüller et al., 2003). In the QC-RI332 cell line this observation is most 
extreme, but in the QC-RI332-6HA cell line it is inconspicuous. Similar differences 
exist also for the G3-RI332 and G3-RI332-6HA cell lines (for details see below).  
5.3. Restoring the wild type phenotype in QC cells 
In order to restore the wild type phenotype in the QC cells, the cells were incubated 
with an excess of galactose. It was described earlier that galactose is connected with a 
complex pathway that involves metabolites of galactose and glucose as well as a 
“cross-talk” between these two hexoses. Apparently, an excess of galactose can 
restore UDP-glucose levels and thus compensate the mutation in the UDP-glucose 
pyrophosphorylase gene (S.E. Moore, unpublished observations).  
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In regular glucose-containing medium, faster degradation of ERAD substrates is 
observed in QC cells when compared to G3 cells (figures 35 and 36). As seen in 
figures 37 to 41, the addition of galactose restores most effects seen in QC cells to 
those of wild type G3 cells (see above). Here, degradation becomes much slower in 
the presence of galactose – even slower than in G3 cells (see figure 41).  Altered levels 
of sugar metabolites could be an explanation for this phenomenon. As seen in figure 
42, the excess of galactose also restores the wild type fibroblast-like morphology of 
QC cells to that of G3 cells. 
5.4. Interaction of ERAD substrates and CNX 
In the previous part of the discussion, it became apparent that the ERAD substrates 
are degraded faster in QC cells than in G3 cells. It was postulated that the faster 
degradation is due to partial avoiding of the CNX cycle by the ERAD substrates in QC 
cells, which usually delays the retrotranslocation and subsequent degradation of 
misfolded proteins. In the following part, the results of the experiments analyzing the 
interaction between CNX and the model ERAD substrates (see 4.3. ERAD substrate – 
calnexin association) will be discussed.  
In figure 51, it becomes obvious that the interaction between RI332/RI332-6HA and 
CNX is much stronger in the G3 cells than in the QC cells. This observation supports 
the hypothesis that the ERAD substrates in QC cells partially avoid entering the CNX 
cycle. It is also evident that the interactions are stronger at chase time point 5’ than at 
chase time point 60’. This finding that is true for all cell lines is also plausible, since 
most of the misfolded proteins should have left the CNX cycle after the delayed 
activity of ER mannosidases. However, it is also discernible that the interaction 
between CNX and RI332-6HA lasts longer than the interaction between CNX and 
RI332 in the G3 cells. This would explain why less trimming variants of RI332-6HA 
are seen in the G3 cell line (figure 32), and why more trimming variants of RI332 are 
seen in the G3 cell line in the presence of ZLLL (figure 31). Due to prolonged 
interaction between RI332-6HA and CNX, the subsequent trimming reactions of 
RI332-6HA largely fail to appear.  
From figures 43 to 50 it becomes evident that the efficiency of non-stringent co-
immunoprecipitation is higher for the endogenous ribophorin I than for the soluble 
variants RI332 and RI332-6HA. Former studies have shown a preferential interaction 
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of the transmembrane protein CNX with membrane-bound substrates, whereas the 
soluble CRT is more frequently associated with substrates that are soluble in the 
lumen of the ER (Benyair, et al., 2011). This would explain the observations in figures 
43 to 50 just described. However, no CRT antibody that worked in non-stringent IP 
was available to use instead of the CNX antibody to test this hypothesis.  
In summary, the following conclusions can be drawn as to the degradation of the 
RI332 and RI332-6HA ERAD substrates in the Chinese hamster fibroblast cell lines G3 
and QC: 
 Faster degradation of the N-glycosylated ERAD substrates is observed in the 
QC cells compared to G3 cells under normal conditions (absence of inhibitors) 
 Properly N-glycosylated ERAD substrates interact with CNX and enter the CNX 
cycle before they retrotranslocate to the cytosol where they are degraded by 
the proteasome 
 Glycoproteins with three glucose molecules (G3 cells in the presence of CST) 
partially avoid entering the CNX cycle 
 Degradation of ERAD substrates is accelerated in presence of glucosidase 
inhibitors in G3 cells, but not so in QC cells 
 Degradation of ERAD substrates depends on mannosidase I in G3 cells, less so 
in QC cells 
 Degradation of ERAD substrates depends on functional proteasomes 
 The ERAD substrates interact stronger with CNX in G3 cells than in QC cells 
 Galactose incubation of QC cells can restore the G3 phenotype 
5.5. Intracellular localization of the ERAD substrates 
The last section of the diploma thesis was dedicated to the intracellular localization of 
the ERAD substrates by indirect immunofluorescence and confocal laser scanning 
microscopy. Not only the localization of the two ERAD substrates (RI332 and RI332-
6HA) under normal conditions in the cells was analyzed, but also whether interfering 
with the ER quality control by using drugs that inhibit initial processing of the N-
linked glycan or proteasomal degradation affects the localization of the two ERAD 
model substrates. 
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Based on data from earlier publications, it could be well assumed that the ERAD 
substrates largely should show an ER localization, although (a) post-ER 
compartment(s) have been invoked in ERAD in the past. In the work of Lederkremer 
and colleagues, a so called quality control compartment that is a sub-compartment of 
the ER and contains a distinct set of ER chaperons has been postulated (Kamhi-
Nesher, et al., 2001; Benyair, et al., 2011).  
In this diploma thesis it should be tested whether the two ERAD substrates RI332 and 
RI332-6HA colocalize with markers of the ER, the ERIC and the Golgi apparatus using 
suitable antibodies for immunofluorescence. The analysis was based on sets of 
images for each condition that were evaluated using a colocalization software 
package from Zeiss followed by statistical analysis with SPSS; specifically two-sided t-
tests of independent samples with appropriate colocalization coefficients were 
performed. 
Just comparing the mean values of the appropriate colocalization coefficients, it 
became evident that there was very little colocalization between the ERAD substrates 
and the Golgi apparatus in all cell lines (mean values of less than 0,06; tables 14 and 
17). Generally, the weighted colocalization coefficients gave even smaller numbers 
than the non-weighted ones. In contrast, there was considerable colocalization 
between the ERAD substrates ad the ER (mean values of more than 0,95; table 16), as 
would be expected. The colocalization between the ERAD substrates and the ERGIC 
was small (mean values of less than 0,009; table 15), comparable or perhaps only 
slightly above the colocalization between the ERAD substrates and the Golgi. 
Interestingly, there appears to be more colocalization between the ERAD substrates 
and the ERGIC in QC cells when compared to G3 cells (table 15; for a statistical 
comparison see below). This could indicate that the ER in the mutant QC cells is more 
“leaky” for glycoproteins than in G3 cells, perhaps due to the lack of glucosylation and 
thus the bypassing of the CNX cycle.    
In table 14, the effects of CST (inhibitor of glucosidase I), KIF (inhibitor of ER 
mannosidase I) and ZLLL (inhibitor of the proteasome) on the colocalization of RI332 
and Golgi apparatus in G3-RI332 and QC-RI332 cells are shown. Assuming that a t-
test significance of less than 5% denotes a significant difference between the two 
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groups (control and inhibitor groups), a significant difference can be observed in the 
G3-RI332 cell line between the control group and the CST group (1% t-test 
significance for the non-weighted colocalization coefficients and 1,3% t-test 
significance for the weighted colocalization coefficients). As discussed earlier (see 5.2. 
Effect of inhibitors on the ERAD substrate degradation) the half life of RI332 decreases 
for approximately 33% in the presence of CST, which may be taken as an indication 
that the CNX cycle is partially avoided, because of the pre-incubation with CST. As a 
consequence, RI332 might be retrotranslocated to the cytosol faster in CST-treated 
cells which could account for the difference in colocalization of RI332 and the Golgi 
apparatus. A similar result was obtained with the tagged RI332-6HA, however, only 
for the weighted colocalization coefficient (0,1% t-test significance), whereas the 
non-weighted colocalization coefficient (79,0% t-test significance) appears to be an 
outlier in this case.  
Surprisingly, the t-test significances of the non-weighted and weighted colocalization 
coefficient are not consistent for the colocalization of RI332 and the Golgi apparatus 
in KIF-treated G3 cells. A 25,3% t-test significance is notable for the non-weighted 
colocalization coefficient (no significant difference), whereas the t-test significance of 
the weighted colocalization coefficient is 0% (significant difference). No reasonable 
explanation is possible for this phenomenon.  
Consistent statistical data are notable for the colocalization coefficients of RI332 and 
the Golgi in G3 cells in presence of ZLLL. The high values of the t-test (98% for the 
non-weighted and 61% for the weighted colocalization coefficients) indicate that 
there is no significant difference between these two groups (control and ZLLL group). 
This is the opposite observation than in the case of the control and CST group. A 
possible explanation for this observation could be that the RI332/Golgi apparatus 
colocalization is higher if the RI332 intracellular localization is extended in the ER (in 
absence of CST), but that its accumulation in the cytosol (in presence of ZLLL) does 
not affect the colocalization with the Golgi apparatus. This could be due to the relative 
close proximity of the Golgi apparatus and the ER in which RI332 is concentrated, 
whereas the retrotranslocated RI332 is more widespread in the cytosol.  
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Interfering with the ER quality control at all levels (inhibition of glucosidase I, ER 
mannosidase I and proteasome) causes a significant difference in the colocalization of 
RI332 and the Golgi apparatus. Plausible explanations for these observations are not 
easily possible. 
Considering all other results (see tables 15 to 17), it is not possible to draw firm 
conclusions as to the influence of inhibitors on the intracellular localization of ERAD 
substrates in each case. The results concerning this part are not fully comprehensible, 
which could be due to methodical limitations (discussed below). 
Similar observations are made in case of the colocalization coefficients for the 
comparisons of different antibody combinations among themselves. As expected, 
there is a significant difference between the HA.11/Giantin and HA.11/Calnexin 
combinations (see table 18). For all cell line comparisons (G3-RI332-6HA vs G3-
RI332-6HA and G3-RI332-6HA vs. QC-RI332-6HA), this antibody combination shows 
0% significance in the t-test (meaning that there is a significant difference). Such 
results were anticipated due to the fact that the Golgi apparatus is restricted to a 
small area, whereas the ER (Calnexin staining) is widely distributed. Different from 
this antibody combination, the combination of HA.11/Giantin and RI lum/CTR433 
shows partially no significant difference. Ideally, no significant difference at all would 
be expected for this antibody combination, because both antibodies (Giantin and 
CTR433) specifically bind to the Golgi apparatus. However, the results shown in table 
19 are not that obvious, because the data are not consistent. In two cell line 
combinations, the expected results appear (no significant differences). In other two 
cell line combinations, there is a significant difference between the two antibody 
combinations (with t-test significances of nearly 0%). CTR433 is a medial-Golgi 
marker (Birkeli, et al., 2003) and giantin can be also found in the cis-Golgi 
(Rodriguez-Gabin, et al., 2009), therefore it would be plausible to find no significant 
differences. Unfortunately, not all desirable comparisons of antibody combinations 
among themselves could be analyzed due to the lack of a suitable mouse monoclonal 
ER marker and a rabbit polyclonal ERGIC marker.   
In all other antibody combination comparisons (see tables 20 to 22), the results are 
as anticipated. A significant difference is notable for i) the colocalization of 
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HA.11/Giantin vs. RI lum/ERGIC53 between all cell lines, ii) the colocalization of 
HA.11/Calnexin vs. RI lum/CTR433 between all cell lines, and iii) HA.11/Calnexin vs. 
RI lum/ERGIC53 between all cell lines. 
It should be noted that the basis for stating colocalization or not is not entirely clear. 
This depends on several factors, apart from differences in background, varying signal 
intensities (that are widely compensated for in the so called weighted colocalization 
coefficients) certainly on the pixel size. Thus, a measure of “true” versus 
“coincidental” colocalization (the latter meaning that a “green” and a “red” signal are 
contained in the same pixel by coincidence, even though there is no colocalization) 
cannot be reliably given.  
Taken together, the immunofluorescence and confocal laser scanning microscopy 
results clearly show a predominant ER localization of the ERAD substrates RI332 and 
RI332-6HA in G3 and QC cells. There is little colocalization with the ERGIC and 
perhaps even less with the Golgi apparatus. The effect of the inhibitors used on the 
localization of the ERAD substrates has not become entirely clear in each case during 
this study.  
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7. Abstract 
7.1. Abstract - English version 
During the journey of secretory proteins from the cytosol to their final destinations, 
they must pass a number of cellular compartments in which folding, modification and 
assembly occurs. The endoplasmic reticulum (ER) is not only an organelle in the 
secretory pathway where folding, modification and assembly occur, but also a 
compartment in which quality control (ERQC) of protein folding takes place.  
Of central importance for the ER quality control is the so-called calnexin cycle (CNX 
cycle). Unfolded and misfolded glycoproteins enter the CNX cycle which may allow 
them to fold properly. Only glycoproteins with specific oligosaccharide motifs can 
enter and leave this cycle. Trimming of the oligosaccharides determines the destiny of 
the glycoproteins, making glycosylation essential for the fate of the secretory 
proteins.  
This diploma thesis is focused on understanding the importance of glycosylation 
(more precise glucosylation) for ERQC and especially ER-associated degradation 
(ERAD). For this purpose, the destiny of two potential ERAD substrates (RI332 and 
RI332-6HA) was analyzed in two different Chinese hamster fibroblast cell lines. One 
cell line (G3) has a fully operative glycosylation, while the other cell line (QC) is not 
able to glucosylate the glycoproteins.  
Results obtained during this diploma thesis clearly point to the importance of 
glucosylation in context of ERAD. Misfolded glycoproteins which are not glucosylated 
are partially able to avoid the CNX cycle. As a consequence, the ERAD substrates enter 
the degradative pathway faster and thus have a half life that is two- to three- times 
shorter. It could be further shown that the ERAD substrates are dramatically 
stabilized when mannose trimming of the oligosaccharide is prevented in G3 cells, 
thus keeping the glycoproteins in the CNX cycle. Stabilization is also observed when 
the proteasome is inhibited.  
The results of this diploma thesis demonstrate a stronger interaction of mono-
glucosylated glycoproteins with CNX as compared to non-glucosylated glycoproteins, 
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and that this interaction is limited in time. In addition, it could be shown that 
galactose is able to revert the glucosylation deficiency in QC cells.   
In the last part of this diploma thesis, the intracellular localization of the two model 
ERAD substrates was analyzed. For this purpose, the immunolabeled RI332 and 
RI332-6HA proteins were visualized by microscopy, and their relative colocalization 
with cellular compartments (ER, ER – Golgi - intermediate compartment (ERGIC) and 
Golgi apparatus) was determined. Both ERAD substrates are predominantly located 
in the ER, and interfering with the ER quality control seems to affect their localization 
in a not fully coherent way.   
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7.2. Abstract (Zusammenfassung) - German version 
Während des Transports von sekretorischen Proteinen vom Zytosol zu deren 
endgültigen Destinationen, durchqueren sie mehrere zelluläre Kompartimente, in 
denen die Proteine gefaltet, modifiziert und assembliert werden. Das 
endoplasmatische Retikulum (ER) ist nicht nur das Organell, wo die Faltung, 
Modifizierung und Assemblierung von Proteinen stattfindet, sondern auch das 
Kompartiment, wo die Qualitätskontrolle (ERQC) erfolgt.  
Von zentraler Bedeutung für die ERQC ist der sog. Calnexin Zyklus (CNX Zyklus). 
Ungefaltete und missgefaltete Proteine gelangen in den CNX Zyklus, der ihnen Zeit 
gibt sich richtig zu falten. Den CNX Zyklus können nur Proteine mit spezifischen 
Oligosaccharid Motiven betreten und verlassen. Das Trimmen des Oligosaccharids 
entscheidet über die Zukunft des Glycoproteins, wodurch die Glykosylierung von 
großer Bedeutung für das Schicksal sekretorischer Glykoproteine ist.  
Diese Diplomarbeit befasst sich mit der Rolle der Glykosylierung (bzw. der 
Glukosylierung) in der ERQC, und vor allem für den ER- assoziierten Proteinabbau 
(ERAD). Dazu wurde das Schicksal von zwei potentiellen ERAD Substraten (RI332 
und RI332-6HA) in zwei unterschiedlichen Zelllinien von Chinesischen Hamster 
Fibroblasten analysiert. Die G3 Zelllinie besitzt eine voll funktionsfähige 
Glykosylierung, während die QC Zelllinie in der Glukosylierung defekt ist.  
Die während dieser Diplomarbeiten erhaltenen Resultate deuten klar auf die 
Wichtigkeit der Glukosylierung im Kontext von ERAD hin. Missgefaltete 
Glykoproteine, die nicht glukosyliert werden, können teilweise den CNX Weg 
umgehen. Als Konsequenz gelangen diese ERAD Substrate schneller in den 
Abbauweg, wodurch sie um das Zwei- bis Dreifache kürzere Halbwertszeiten haben. 
Es konnte weiters gezeigt werden, dass die ERAD substrate dramatisch stabilisiert 
werden, wenn das Mannose – Trimming des Oligosaccharids in G3 Zellen blockiert 
wird, wodurch die Glykoproteine im CNX Zyklus gebunden bleiben. Stabilisierung 
erfolgt auch nach Inhibierung des Proteasoms.  Die Resultate der Diplomarbeit 
deuten auch auf eine stärkere, aber zeitlich begrenzte, Interaktion von mono-
glukosylierten Proteinen mit CNX hin, im Unterschied zur praktisch fehlenden 
Interaktion von nicht glukosylierten Proteinen mit CNX. Weiteres konnte gezeigt 
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werden, dass ein Überschuss an Galaktose den Glukosylierungs- Defekt in QC Zellen 
kompensieren kann.  
Im letzten Teil der Diplomarbeit wurde die intrazelluläre Lokalisierung der zwei 
ERAD Substrate analysiert. Dafür wurden die mit Antikörpern markierten Substrat-
Proteine (RI332 und RI332-6HA) mikroskopisch visualisiert, und die relative 
Colokalisierung mit zellulären Kompartimenten ermittelt (ER, ER – Golgi – 
Intermediär – Kompartiment (ERGIC) und Golgi – Apparat). Die beiden ERAD – 
Substrate lokalisieren überwiegend zum ER und ein Einfluss der pharmakologischen 
Interventionen von ERQC auf die Lokalisierung war nicht in jedem Fall eindeutig 
erkennbar. 
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